<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02130635</url>
  </required_header>
  <id_info>
    <org_study_id>115119</org_study_id>
    <nct_id>NCT02130635</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <official_title>A Double-Blind (Sponsor Unblind), Placebo Controlled, Randomised, Parallel Group Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of GSK2269557 Administered as a Dry Powder to COPD Patients and Assessment of Dose Response Using Sputum Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, double-blind, placebo controlled, parallel group study to evaluate the
      safety, tolerability, pharmacokinetics and dose response of multiple doses of GSK2269557
      administered as a dry powder in COPD subjects. Pharmacodynamic effects on biomarkers will
      also be assessed. This study will have two parts. In Part A, subjects will be randomized to
      active or placebo treatment in a 3:1 ratio and in Part B, to placebo or one of the six doses
      of active treatment in an equal ratio. A sufficient number of COPD subjects (male and female
      of non-child bearing potential) will be screened to ensure that approximately 30 subjects are
      enrolled and at least 20 evaluable subjects are obtained for Part A and approximately 35
      subjects will be enrolled for Part B. In both the parts, subjects will receive study
      treatment once daily for 14 consecutive days. Placebo control will be included for a valid
      evaluation of adverse events attributable to treatment versus those independent of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 1, 2014</start_date>
  <completion_date type="Actual">August 18, 2015</completion_date>
  <primary_completion_date type="Actual">August 1, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Number of Participants With at Least One Non-serious Adverse Event (AE), Serious Adverse Event (SAE), or Drug-related Adverse Event</measure>
    <time_frame>From the start of study treatment until follow-up (assessed for approximately 19 days)</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition, associated with liver injury and impaired liver function defined as alanine aminotransferase &gt;=3 x upper limit of normal (ULN), and total bilirubin &gt;=2 x ULN or international normalized ratio &gt;1.5. AEs were classified as potentially drug-related, based on the investigator's judgment. Refer to the general AE/SAE module for a list of AEs and SAEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Counts of White Blood Cells (WBC), Total Neutrophils (Total Absolute Neutrophil Count [ANC]), Lymphocytes, Monocytes, Eosinophils, Basophils, and Platelets at the Indicated Time Points</measure>
    <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
    <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) at the Indicated Time Points</measure>
    <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 h post-dose)</time_frame>
    <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. MCHC is one of the red blood cell (RBC) indices. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Hematocrit at the Indicated Time Points</measure>
    <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
    <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Counts of RBCs and Reticulocytes at the Indicated Time Points</measure>
    <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
    <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at the Indicated Time Points</measure>
    <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
    <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. MCH is one of the red blood cell indices. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Mean Corpuscle Volume (MCV) at the Indicated Time Points</measure>
    <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
    <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. MCV is one of the RBC indices. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Albumin and Total Protein at the Indicated Time Points</measure>
    <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
    <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) at the Indicated Time Points</measure>
    <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
    <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Creatinine, Bilirubin, and Total Bilirubin at the Indicated Time Points</measure>
    <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
    <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Calcium, Potassium, Sodium, Glucose, and Blood Urea Nitrogen (BUN) at the Indicated Time Points</measure>
    <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
    <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants Meeting Criteria of Potential Clinical Importance for Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), and Heart Rate (HR) at Any Visit Post-Baseline</measure>
    <time_frame>Day 1, Day 7, and Day 14</time_frame>
    <description>Baseline was the Day 1 pre-dose measurement. Vital signs (SBP, DBP, and HR) were measured at Day 1 (30 minutes [min] and 6 h post-dose), Day 7 (pre-dose), and Day 14 (24 h post-dose). Potential clinical concern range for SBP was &lt;85 millimeters of mercury (mmHg) (low) and &gt;160 mmHg (high), for DBP &lt;45 mmHg (low) and &gt;100 mmHg (high) and for HR &lt;40 bpm and &gt;110 bpm. All measurements were obtained in supine position, after a 5-minute rest. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of Participants With Normal and Abnormal (Clinically Significant or Not Clinically Significant) Findings in 12-lead Electrocardiogram (ECG) at Any Visit Post-Baseline</measure>
    <time_frame>Day 1, Day 7, and Day 14</time_frame>
    <description>Baseline was the Day 1 (pre-dose) measurement. Single 12-lead ECGs were obtained using an ECG machine that automatically calculates the HR and measures PR, QRS, QT, and corrected QT intervals. Clinical significance was judged by the investigator. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Baseline in Forced Expiratory Volume in One Second (FEV1) and Forced Vital Capacity (FVC) at the Indicated Time Points</measure>
    <time_frame>Baseline (Day 1 [pre-dose]), Day 1 (1 h post-dose), Day 7 (pre-dose and 1 h post-dose), and Day 14 (24 h post-dose)</time_frame>
    <description>Baseline is Day 1 pre-dose. FEV1 and FVC are measures of lung function. FEV1 is defined as the maximal amount of air that can be forcefully exhaled in one second. FVC is defined as the maximum amount of air that can be forcibly blown out after a maximum inspiration. FEV1 and FVC measurements were repeated until three technically acceptable measurements (within 150 milliliters of each other) had been made. Only the best of three measurements were recorded. Baseline was the maximum of the planned pre-dose measurements on Day 1. Change from Baseline at any post-dose time point was calculated as the post-dose value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Adjusted Median Response of Cytokine (Interleukin 6 [IL6], Interleukin 8 [IL8], Tumor Necrosis Factor Alpha [TNFalpha]) Concentrations in Induced Sputum, on Day 7 and Day 14</measure>
    <time_frame>Day 7 (pre-dose) and Day 14 (24 h post-dose)</time_frame>
    <description>This outcome measure was used to estimate the inhibition levels of various doses of GSK2269557 by analyzing inflammatory cytokines IL6, IL8, and TNF alpha using Bayesian methods of statistical analysis, using non-informative prior distributions for all modeling parameters. Posterior medians (adjusted median response) and 95% credible intervals are reported here as medians and 95% confidence intervals respectively. 95% credible interval is reported as 2-sided 95% confidence in the statistical analyses. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Day 1 Plasma Concentration of GSK2269577 up to 6 Hours Post Dose</measure>
    <time_frame>Day 1 (Pre-dose, 5 min, 30 min, 1, 2, 4 &amp; 6 hours post-dose)</time_frame>
    <description>A 2 mL blood sample for pharmacokinetic (PK) analysis was collected at each of the indicated time point. Only those participants who were available at the indicated time points were analyzed (represented by n=X in the category titles). A value of NA indicates that the geometric mean or 95% confidence interval is not available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Day 1 Plasma Concentration of GSK2269577 up to 6 Hours Post Dose</measure>
    <time_frame>Pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, and 6 h post-dose on Day 1</time_frame>
    <description>A 2 mL blood sample for pharmacokinetic (PK) analysis was collected at each of the indicated time point. Concentration measurements were log-transformed. Only those participants who were available at the indicated time points were analyzed (represented by n=X,X in the category titles). A value of NA indicates that the geometric mean or 95% confidence interval is not available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Maximum Observed Plasma Concentration (Cmax) of GSK2269577 on Day 7</measure>
    <time_frame>Day 7 immediately after dosing</time_frame>
    <description>Blood samples were collected to determine the plasma concentrations of GSK2269577 immediately after dosing on Day 7. Day 7 sampling could be done on Day 7 or Day 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Maximum Observed Plasma Concentration (Cmax) of GSK2269577 on Day 7</measure>
    <time_frame>Day 7 immediately after dosing</time_frame>
    <description>Blood samples were collected to determine the plasma concentrations of GSK2269577 immediately after dosing on Day 7. Concentration values were log-transformed. Day 7 sampling could be done on Day 7 or Day 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Trough Concentration (Ctau) of GSK2269577 on Day 7 and Day 15</measure>
    <time_frame>Day 7 and Day 15</time_frame>
    <description>Blood samples were collected to determine the (trough) plasma concentration of GSK2269577 on Day 7 (pre-dose) and Day 15 (24 hours after dosing on Day 14). Day 7 assessments could be done either on Day 7 or on Day 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Trough Concentration (Ctau) of GSK2269577 on Day 7 and Day 15</measure>
    <time_frame>Day 7 and Day 15</time_frame>
    <description>Blood samples were collected to determine the (trough) plasma concentration of GSK2269577 on Day 7 (pre-dose) and Day 15 (24 hours after dosing on Day 14). Day 7 assessments could be done either on Day 7 or on Day 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of Times Rescue Medication Was Used by Participants Daily, During the Treatment Period</measure>
    <time_frame>Day 1 to Day 15</time_frame>
    <description>Rescue medication was identified from concomitant medication records and the patient diaries which were provided to the participants to record data throughout the treatment period. Only participants who used rescue medication were analyzed. The value NA indicates that the standard deviation could not be calculated as only one participant was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of Participants With at Least One Non-serious Adverse Event (AE), Serious Adverse Event (SAE), or Drug-related Adverse Event</measure>
    <time_frame>From the start of study treatment until follow-up (assessed for approximately 19 days)</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition, associated with liver injury and impaired liver function defined as alanine aminotransferase &gt;=3 x upper limit of normal (ULN), and total bilirubin &gt;=2 x ULN or international normalized ratio &gt;1.5. AEs were classified as potentially drug-related, based on the investigator's judgment. Refer to the general AE/SAE module for a list of AEs and SAEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in Counts of Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets, White Blood Cells (WBC), Total Neutrophils (Total ANC) at the Indicated Time Points</measure>
    <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
    <description>Blood samples were collected for measurement for the indicated tests. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) at the Indicated Time Points</measure>
    <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
    <description>Blood samples were collected for measurement for the indicated tests. MCHC is one of the red blood cell (RBC) indices. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in Counts of RBCs and Reticulocytes at the Indicated Time Points</measure>
    <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
    <description>Blood samples were collected for measurement for the indicated tests. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in Hematocrit at the Indicated Time Points</measure>
    <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
    <description>Blood samples were collected for measurement for the indicated tests. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at the Indicated Time Points</measure>
    <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
    <description>Blood samples were collected for measurement for the indicated tests. MCH is one of the red blood cell indices. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in Mean Corpuscle Volume (MCV) at the Indicated Time Points</measure>
    <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
    <description>Blood samples were collected for measurement for the indicated tests. MCV is one of the RBC indices. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in Albumin and Total Protein at the Indicated Time Points</measure>
    <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
    <description>Blood samples were collected for measurement for the indicated tests. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) at the Indicated Time Points</measure>
    <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
    <description>Blood samples were collected for measurement for the indicated tests. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in Creatinine, Bilirubin, and Total Bilirubin at the Indicated Time Points</measure>
    <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
    <description>Blood samples were collected for measurement for the indicated tests. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in Calcium, Potassium, Sodium, Glucose, and Blood Urea Nitrogen (BUN) at the Indicated Time Points</measure>
    <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
    <description>Blood samples were collected for measurement for the indicated tests. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of Participants Meeting Criteria of Potential Clinical Importance for Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), and Heart Rate (HR) at Any Visit Post-Baseline</measure>
    <time_frame>Day 1, Day 7, and Day 14</time_frame>
    <description>Baseline was the Day 1 pre-dose measurement. Vital signs (SBP, DBP, and HR) were measured at Day 1 (30 minutes [min] and 6 h post-dose), Day 7 (pre-dose), and Day 14 (24 h post-dose). All measurements were obtained in supine position, after a 5-minute rest. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of Participants With Normal and Abnormal (Clinically Significant or Not Clinically Significant) Findings in 12-lead Electrocardiogram (ECG) at Any Visit Post-Baseline</measure>
    <time_frame>Day 1, Day 7, and Day 14</time_frame>
    <description>Baseline was the Day 1 (pre-dose) measurement. Single 12-lead ECGs were obtained using an ECG machine that automatically calculates the HR and measures PR, QRS, QT, and corrected QT intervals. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Forced Expiratory Volume in One Second (FEV1) and Forced Vital Capacity (FVC) at Screening and Follow-up</measure>
    <time_frame>Screening (up to 30 days prior to Day 1) and Follow-up (approximately Day 19)</time_frame>
    <description>FEV1 and FVC are measures of lung function. FEV1 is defined as the maximal amount of air that can be forcefully exhaled in one second. FVC is defined as the maximum amount of air that can be forcibly blown out after a maximum inspiration. FEV1 and FVC measurements were repeated until three technically acceptable measurements (within 150 milliliters of each other) had been made. Only the best of three measurements were recorded.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Part A: GSK2269557 1000 MCG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 2 inhalations (2 x GSK2269557 500 mcg = total dose of 1000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive 2 inhalations of placebo once daily for 14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: GSK2269557 100 MCG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 4 inhalations (1 x GSK2269557 100 mcg and 3 x Placebo = total dose of 100 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: GSK2269557 200 MCG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 200 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: GSK2269557 500 MCG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 4 inhalations (1 x GSK2269557 500 mcg and 3 x Placebo = total dose of 500 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days, once daily for 14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: GSK2269557 700 MCG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 4 inhalations (1 x GSK2269557 500 mcg, 2 x GSK2269557 100 mcg and 1 x Placebo = total dose of 700 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: GSK2269557 1000 MCG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 1000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: GSK2269557 2000 MCG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 2000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive 4 inhalations of placebo once daily for 14 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2269557 100 MCG</intervention_name>
    <description>100 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device</description>
    <arm_group_label>Part B: GSK2269557 700 MCG</arm_group_label>
    <arm_group_label>Part B: GSK2269557 100 MCG</arm_group_label>
    <arm_group_label>Part B: GSK2269557 200 MCG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2269557 500 MCG</intervention_name>
    <description>500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device</description>
    <arm_group_label>Part B: GSK2269557 700 MCG</arm_group_label>
    <arm_group_label>Part A: GSK2269557 1000 MCG</arm_group_label>
    <arm_group_label>Part B: GSK2269557 500 MCG</arm_group_label>
    <arm_group_label>Part B: GSK2269557 1000 MCG</arm_group_label>
    <arm_group_label>Part B: GSK2269557 2000 MCG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>Lactose administered using a matching dry powder inhaler device</description>
    <arm_group_label>Part B: GSK2269557 700 MCG</arm_group_label>
    <arm_group_label>Part B: GSK2269557 100 MCG</arm_group_label>
    <arm_group_label>Part B: GSK2269557 500 MCG</arm_group_label>
    <arm_group_label>Part B: GSK2269557 1000 MCG</arm_group_label>
    <arm_group_label>Part B: GSK2269557 200 MCG</arm_group_label>
    <arm_group_label>Part A: PLACEBO</arm_group_label>
    <arm_group_label>Part B: PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has a confirmed and established diagnosis of COPD, as defined by the
             Global Initiative for Chronic Obstructive lung Disease (GOLD) guidelines.

          -  Male or female of non-child bearing potential between 40 and 75 years of age
             inclusive, at the time of signing the informed consent.

          -  The subject has a post-bronchodilator [400 microgram (mcg) salbutamol] Maximal amount
             of air FEV1/FVC &lt;0.7 and FEV1 &gt;=40% to &lt;=80% of predicted (Predictions should be
             according to the European Community of Coal and Steel (ECCS) equations).

          -  Subject is a smoker or an ex-smoker with a smoking history of at least 10 pack years
             (pack years = (cigarettes per day smoked/20) x number of years smoked)).

          -  The subject is able to produce &gt;100 milligram (mg) of sputum at screening.

          -  Body weight &gt;=45 kilogram (kg) and body mass index (BMI) within the range 17 - 32
             kg/square meter (m^2) (inclusive).

          -  A female subject is eligible to participate if she is of: Non-childbearing potential
             defined as pre-menopausal females with a documented tubal ligation, hysterectomy,
             salpingo-oophrectomy or oophrectomy; or postmenopausal defined as 12 months of
             spontaneous amenorrhea [in questionable cases a blood sample with simultaneous
             follicle stimulating hormone (FSH) &gt; 40 milli-International units (MIU)/millilitre
             (mL) and estradiol &lt; 40 picogram (pg)/mL (&lt;147 picomole(pmol)/Liter [L]) is
             confirmatory]. [Females on hormone replacement therapy (HRT) and whose menopausal
             status is in doubt will be required to use one of the contraception methods, if they
             wish to continue their HRT during the study. Otherwise, they must discontinue HRT to
             allow confirmation of post-menopausal status prior to study enrolment. For most forms
             of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood
             draw; this interval depends on the type and dosage of HRT. Following confirmation of
             their post-menopausal status, they can resume use of HRT during the study without use
             of a contraceptive method.]; or has only same-sex partners, when this is her preferred
             and usual lifestyle.

          -  Male subjects with female partners of child-bearing potential must agree to use one of
             the contraception methods. This criterion must be followed from the time of the first
             dose of study medication until the follow-up visit.

          -  Based on averaged QTcF values of triplicate ECGs obtained over a brief recording
             period (e.g. 5 minutes): QTcF &lt;450 millisecond (msec); or QTcF&lt;480 msec in subjects
             with right bundle branch block.

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form.

          -  A subject with a clinical abnormality or laboratory parameter(s) which is/are not
             specifically listed in the inclusion or exclusion criteria, outside the reference
             range for the population being studied may be included if the investigator [in
             consultation with the Glaxosmithkline (GSK) medical monitor if required] documents
             that the finding is unlikely to introduce additional risk factors and will not
             interfere with the study procedures.

        Exclusion Criteria:

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome, asymptomatic gallstones and
             cholecystectomy).

          -  Subjects who have a past or current medical condition or diseases that are not well
             controlled and, which as judged by the Investigator, may affect subject safety or
             influence the outcome of the study. (Note: Patients with adequately treated and well
             controlled concurrent medical conditions (e.g. hypertension) are permitted to be
             entered into the study).

          -  Subject has a diagnosis of active tuberculosis, lung cancer, clinically overt
             bronchiectasis, pulmonary fibrosis, asthma or any other respiratory condition that
             might, in the opinion of the Investigator, compromise the safety of the subject or
             affect the interpretation of the results.

          -  History of regular alcohol consumption within 6 months of the study defined as an
             average weekly intake of &gt;28 units for males or &gt;21 units for females. One unit is
             equivalent to 8 gram of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass
             (125 mL) of wine or 1 (25 mL) measure of spirits.

          -  History of sensitivity to any of the study medications, or components (such as
             lactose) thereof or a history of drug or other allergy that, in the opinion of the
             investigator or GSK Medical Monitor, contraindicates their participation.

          -  A positive test for Human immunodeficiency virus (HIV) antibody - tested according to
             local policies.

          -  The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that
             will be screened for include cannabinoids, amphetamines, barbiturates, cocaine and
             opiates. The detection of drugs (e.g. benzodiazepines, opiates) taken for a legitimate
             medical purpose would not necessarily be an exclusion to study participation. The
             detection of alcohol would not be an exclusion at screening but would need to be
             negative pre-dose and during the study.

          -  A positive pre-study Hepatitis B surface antigen (HBs-Ag) or positive total hepatitis
             B core antibody (anti-HBc IgM) or positive Hepatitis C antibody result within 3 months
             of screening.

          -  Pregnant females as determined by positive urine human chorionic gonadotropin (hCG)
             test at screening or prior to dosing.

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500 mL within a 56 day period.

          -  Lactating females.

          -  The subject has participated in a clinical trial and has received an investigational
             product within the following time period prior to the first dosing day in the current
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the
             investigational product (whichever is longer).

          -  Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day.

          -  Subject has poorly controlled or unstable COPD, defined as the occurrence of any of
             the following: Either: acute worsening of COPD (an exacerbation) that is managed by
             the subject at home requiring treatment with corticosteroids and/or antibiotics in the
             4 weeks prior to the screening visit; or more than two exacerbations in the previous 2
             months prior to the screening visit that required a course of oral corticosteroids
             and/or antibiotics, or for which the subject was hospitalised.

          -  Subject has had a respiratory tract infection treated with antibiotics in the 4 weeks
             prior to first dose.

          -  Subject requires regular treatment with oral corticosteroids or has received oral or
             parenteral corticosteroids within 4 weeks of screening.

          -  Vulnerable subject (e.g., person kept in detention).

          -  The subject is not able to understand and communicate in German or native language.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grosshansdorf</city>
        <state>Schleswig-Holstein</state>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2014</study_first_submitted>
  <study_first_submitted_qc>May 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2014</study_first_posted>
  <results_first_submitted>January 10, 2017</results_first_submitted>
  <results_first_submitted_qc>April 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2017</results_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PI3Kd</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>dry powder inhaler</keyword>
  <keyword>GSK2269557</keyword>
  <keyword>safety</keyword>
  <keyword>COPD subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This study was comprised of two parts. In Part A, participants were randomized to active or placebo treatment in a 3:1 ratio and in Part B, to placebo or one of the six doses of active treatment in an equal ratio. Each part comprised a separate sample of participants.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A: Placebo</title>
          <description>Participants received 2 inhalations of matching placebo once daily for 14 consecutive days.</description>
        </group>
        <group group_id="P2">
          <title>Part A: GSK2269577 1000 µg</title>
          <description>Participants received repeat doses of GSK2269557 1000 micrograms (µg) (2 inhalations of 500 µg each from a single device) administered as a dry powder inhalation, once daily for 14 consecutive days.</description>
        </group>
        <group group_id="P3">
          <title>Part B: Placebo</title>
          <description>Participants received four inhalations of matching placebo (from four inhalation devices) once daily for 14 consecutive days.</description>
        </group>
        <group group_id="P4">
          <title>Part B: GSK2269577 100 µg</title>
          <description>Participants received repeat doses of GSK2269557 100 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
        </group>
        <group group_id="P5">
          <title>Part B: GSK2269577 200 µg</title>
          <description>Participants received repeat doses of GSK2269557 200 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
        </group>
        <group group_id="P6">
          <title>Part B: GSK2269577 500 µg</title>
          <description>Participants received repeat doses of GSK2269557 500 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
        </group>
        <group group_id="P7">
          <title>Part B: GSK2269577 700 µg</title>
          <description>Participants received repeat doses of GSK2269557 700 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 100 µg, 500 µg, or placebo.</description>
        </group>
        <group group_id="P8">
          <title>Part B: GSK2269577 1000 µg</title>
          <description>Participants received repeat doses of GSK2269557 1000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
        </group>
        <group group_id="P9">
          <title>Part B: GSK2269577 2000 µg</title>
          <description>Participants received repeat doses of GSK2269557 2000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 500 µg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A-Safety and Tolerability</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part B-Dose-Response Relationship</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part A: Placebo</title>
          <description>Participants received 2 inhalations of matching placebo once daily for 14 consecutive days.</description>
        </group>
        <group group_id="B2">
          <title>Part A: GSK2269577 1000 µg</title>
          <description>Participants received repeat doses of GSK2269557 1000 micrograms (µg) (2 inhalations of 500 µg each from a single device) administered as a dry powder inhalation, once daily for 14 consecutive days.</description>
        </group>
        <group group_id="B3">
          <title>Part B: Placebo</title>
          <description>Participants received four inhalations of matching placebo (from four inhalation devices) once daily for 14 consecutive days.</description>
        </group>
        <group group_id="B4">
          <title>Part B: GSK2269577 100 µg</title>
          <description>Participants received repeat doses of GSK2269557 100 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
        </group>
        <group group_id="B5">
          <title>Part B: GSK2269577 200 µg</title>
          <description>Participants received repeat doses of GSK2269557 200 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
        </group>
        <group group_id="B6">
          <title>Part B: GSK2269577 500 µg</title>
          <description>Participants received repeat doses of GSK2269557 500 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
        </group>
        <group group_id="B7">
          <title>Part B: GSK2269577 700 µg</title>
          <description>Participants received repeat doses of GSK2269557 700 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 100 µg, 500 µg, or placebo.</description>
        </group>
        <group group_id="B8">
          <title>Part B: GSK2269577 1000 µg</title>
          <description>Participants received repeat doses of GSK2269557 1000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
        </group>
        <group group_id="B9">
          <title>Part B: GSK2269577 2000 µg</title>
          <description>Participants received repeat doses of GSK2269557 2000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 500 µg.</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="5"/>
            <count group_id="B6" value="5"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="5"/>
            <count group_id="B9" value="5"/>
            <count group_id="B10" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Data provided for Part A</description>
          <population>N=28</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.1" spread="5.81"/>
                    <measurement group_id="B2" value="60.5" spread="6.68"/>
                    <measurement group_id="B10" value="61.7" spread="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Data for Part B is presented.</description>
          <population>N=36</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="5"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="5"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="5"/>
                    <count group_id="B9" value="5"/>
                    <count group_id="B10" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="64.4" spread="4.45"/>
                    <measurement group_id="B4" value="61.6" spread="4.56"/>
                    <measurement group_id="B5" value="62.2" spread="8.23"/>
                    <measurement group_id="B6" value="65.4" spread="5.81"/>
                    <measurement group_id="B7" value="64.7" spread="7.26"/>
                    <measurement group_id="B8" value="62.4" spread="9.24"/>
                    <measurement group_id="B9" value="62.4" spread="6.43"/>
                    <measurement group_id="B10" value="63.3" spread="6.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="5"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="5"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="5"/>
                    <count group_id="B9" value="5"/>
                    <count group_id="B10" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White-White/Caucasian/European Heritage</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="21"/>
                    <count group_id="B3" value="5"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="5"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="5"/>
                    <count group_id="B9" value="5"/>
                    <count group_id="B10" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part A: Number of Participants With at Least One Non-serious Adverse Event (AE), Serious Adverse Event (SAE), or Drug-related Adverse Event</title>
        <description>An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition, associated with liver injury and impaired liver function defined as alanine aminotransferase &gt;=3 x upper limit of normal (ULN), and total bilirubin &gt;=2 x ULN or international normalized ratio &gt;1.5. AEs were classified as potentially drug-related, based on the investigator's judgment. Refer to the general AE/SAE module for a list of AEs and SAEs.</description>
        <time_frame>From the start of study treatment until follow-up (assessed for approximately 19 days)</time_frame>
        <population>Safety Population: all participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Participants received 2 inhalations of matching placebo once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part A: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 micrograms (µg) (2 inhalations of 500 µg each from a single device) administered as a dry powder inhalation, once daily for 14 consecutive days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Number of Participants With at Least One Non-serious Adverse Event (AE), Serious Adverse Event (SAE), or Drug-related Adverse Event</title>
          <description>An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition, associated with liver injury and impaired liver function defined as alanine aminotransferase &gt;=3 x upper limit of normal (ULN), and total bilirubin &gt;=2 x ULN or international normalized ratio &gt;1.5. AEs were classified as potentially drug-related, based on the investigator's judgment. Refer to the general AE/SAE module for a list of AEs and SAEs.</description>
          <population>Safety Population: all participants who received at least one dose of study treatment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one drug-related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Counts of White Blood Cells (WBC), Total Neutrophils (Total Absolute Neutrophil Count [ANC]), Lymphocytes, Monocytes, Eosinophils, Basophils, and Platelets at the Indicated Time Points</title>
        <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Participants received 2 inhalations of matching placebo once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part A: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 micrograms (µg) (2 inhalations of 500 µg each from a single device) administered as a dry powder inhalation, once daily for 14 consecutive days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Counts of White Blood Cells (WBC), Total Neutrophils (Total Absolute Neutrophil Count [ANC]), Lymphocytes, Monocytes, Eosinophils, Basophils, and Platelets at the Indicated Time Points</title>
          <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>10^9 cells per liter (GI/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WBC; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.736" spread="0.937"/>
                    <measurement group_id="O2" value="-0.080" spread="1.387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.140" spread="1.220"/>
                    <measurement group_id="O2" value="-0.510" spread="0.947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ANC; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.664" spread="0.624"/>
                    <measurement group_id="O2" value="-0.363" spread="1.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ANC; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.153" spread="0.887"/>
                    <measurement group_id="O2" value="-0.547" spread="0.977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.033" spread="0.321"/>
                    <measurement group_id="O2" value="0.172" spread="0.597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.049" spread="0.197"/>
                    <measurement group_id="O2" value="0.030" spread="0.245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.036" spread="0.074"/>
                    <measurement group_id="O2" value="0.046" spread="0.149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.039" spread="0.178"/>
                    <measurement group_id="O2" value="-0.022" spread="0.116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.006" spread="0.051"/>
                    <measurement group_id="O2" value="0.032" spread="0.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" spread="0.085"/>
                    <measurement group_id="O2" value="0.010" spread="0.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.001" spread="0.006"/>
                    <measurement group_id="O2" value="0.006" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" spread="0.013"/>
                    <measurement group_id="O2" value="0.002" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="20.58"/>
                    <measurement group_id="O2" value="17.9" spread="36.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="21.80"/>
                    <measurement group_id="O2" value="23.5" spread="37.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) at the Indicated Time Points</title>
        <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. MCHC is one of the red blood cell (RBC) indices. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 h post-dose)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Participants received 2 inhalations of matching placebo once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part A: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 micrograms (µg) (2 inhalations of 500 µg each from a single device) administered as a dry powder inhalation, once daily for 14 consecutive days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) at the Indicated Time Points</title>
          <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. MCHC is one of the red blood cell (RBC) indices. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>Grams/Liter (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="6.63"/>
                    <measurement group_id="O2" value="1.6" spread="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="6.97"/>
                    <measurement group_id="O2" value="1.0" spread="4.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="7.32"/>
                    <measurement group_id="O2" value="-2.2" spread="4.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="4.39"/>
                    <measurement group_id="O2" value="-2.4" spread="6.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Hematocrit at the Indicated Time Points</title>
        <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Participants received 2 inhalations of matching placebo once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part A: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 micrograms (µg) (2 inhalations of 500 µg each from a single device) administered as a dry powder inhalation, once daily for 14 consecutive days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Hematocrit at the Indicated Time Points</title>
          <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" spread="0.023"/>
                    <measurement group_id="O2" value="0.007" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.011" spread="0.019"/>
                    <measurement group_id="O2" value="0.006" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Counts of RBCs and Reticulocytes at the Indicated Time Points</title>
        <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Participants received 2 inhalations of matching placebo once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part A: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 micrograms (µg) (2 inhalations of 500 µg each from a single device) administered as a dry powder inhalation, once daily for 14 consecutive days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Counts of RBCs and Reticulocytes at the Indicated Time Points</title>
          <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>10^12 cells/Liter (TI/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RBCs; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.023" spread="0.230"/>
                    <measurement group_id="O2" value="0.060" spread="0.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBCs; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.119" spread="0.201"/>
                    <measurement group_id="O2" value="0.063" spread="0.160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005" spread="0.014"/>
                    <measurement group_id="O2" value="0.003" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.009" spread="0.014"/>
                    <measurement group_id="O2" value="0.003" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at the Indicated Time Points</title>
        <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. MCH is one of the red blood cell indices. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Participants received 2 inhalations of matching placebo once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part A: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 micrograms (µg) (2 inhalations of 500 µg each from a single device) administered as a dry powder inhalation, once daily for 14 consecutive days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at the Indicated Time Points</title>
          <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. MCH is one of the red blood cell indices. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>Picograms (pg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MCH; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="0.602"/>
                    <measurement group_id="O2" value="-0.06" spread="0.440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCH; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="0.586"/>
                    <measurement group_id="O2" value="-0.23" spread="0.593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Mean Corpuscle Volume (MCV) at the Indicated Time Points</title>
        <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. MCV is one of the RBC indices. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Participants received 2 inhalations of matching placebo once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part A: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 micrograms (µg) (2 inhalations of 500 µg each from a single device) administered as a dry powder inhalation, once daily for 14 consecutive days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Mean Corpuscle Volume (MCV) at the Indicated Time Points</title>
          <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. MCV is one of the RBC indices. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>Femtoliters (fL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MCV; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.687"/>
                    <measurement group_id="O2" value="0.43" spread="0.697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCV; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.848"/>
                    <measurement group_id="O2" value="-0.03" spread="1.193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Albumin and Total Protein at the Indicated Time Points</title>
        <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Participants received 2 inhalations of matching placebo once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part A: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 micrograms (µg) (2 inhalations of 500 µg each from a single device) administered as a dry powder inhalation, once daily for 14 consecutive days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Albumin and Total Protein at the Indicated Time Points</title>
          <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="2.230"/>
                    <measurement group_id="O2" value="0.80" spread="1.576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Day 14, 24 h post doseTotal protein; Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="2.379"/>
                    <measurement group_id="O2" value="0.52" spread="2.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="3.619"/>
                    <measurement group_id="O2" value="1.28" spread="2.599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="3.887"/>
                    <measurement group_id="O2" value="1.15" spread="2.606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) at the Indicated Time Points</title>
        <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Participants received 2 inhalations of matching placebo once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part A: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 micrograms (µg) (2 inhalations of 500 µg each from a single device) administered as a dry powder inhalation, once daily for 14 consecutive days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) at the Indicated Time Points</title>
          <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>International Units per Liter (IU/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" spread="2.585"/>
                    <measurement group_id="O2" value="-0.61" spread="2.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="2.667"/>
                    <measurement group_id="O2" value="-0.40" spread="4.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="6.937"/>
                    <measurement group_id="O2" value="1.14" spread="8.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.23" spread="6.522"/>
                    <measurement group_id="O2" value="-0.21" spread="9.785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.14" spread="7.674"/>
                    <measurement group_id="O2" value="-1.03" spread="3.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="4.750"/>
                    <measurement group_id="O2" value="-0.71" spread="2.592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" spread="2.203"/>
                    <measurement group_id="O2" value="0.11" spread="2.550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.96" spread="2.873"/>
                    <measurement group_id="O2" value="-0.46" spread="4.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Creatinine, Bilirubin, and Total Bilirubin at the Indicated Time Points</title>
        <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Participants received 2 inhalations of matching placebo once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part A: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 micrograms (µg) (2 inhalations of 500 µg each from a single device) administered as a dry powder inhalation, once daily for 14 consecutive days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Creatinine, Bilirubin, and Total Bilirubin at the Indicated Time Points</title>
          <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>Micromoles/Liter (micromol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" spread="4.385"/>
                    <measurement group_id="O2" value="-0.62" spread="5.104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.64" spread="6.035"/>
                    <measurement group_id="O2" value="0.07" spread="3.259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.419"/>
                    <measurement group_id="O2" value="0.04" spread="0.398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.496"/>
                    <measurement group_id="O2" value="0.10" spread="0.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="2.447"/>
                    <measurement group_id="O2" value="0.02" spread="2.590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="2.805"/>
                    <measurement group_id="O2" value="0.78" spread="1.720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Calcium, Potassium, Sodium, Glucose, and Blood Urea Nitrogen (BUN) at the Indicated Time Points</title>
        <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Participants received 2 inhalations of matching placebo once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part A: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 micrograms (µg) (2 inhalations of 500 µg each from a single device) administered as a dry powder inhalation, once daily for 14 consecutive days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Calcium, Potassium, Sodium, Glucose, and Blood Urea Nitrogen (BUN) at the Indicated Time Points</title>
          <description>Blood samples were collected for measurement for the indicated tests. Baseline is Day 1 pre-dose. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>Millimoles per Liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.033" spread="0.0535"/>
                    <measurement group_id="O2" value="0.033" spread="0.0617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.033" spread="0.0850"/>
                    <measurement group_id="O2" value="0.029" spread="0.0588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.053" spread="0.3333"/>
                    <measurement group_id="O2" value="0.012" spread="0.2888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.161" spread="0.2659"/>
                    <measurement group_id="O2" value="0.024" spread="0.4914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.103" spread="0.2279"/>
                    <measurement group_id="O2" value="0.011" spread="0.3539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.161" spread="0.2562"/>
                    <measurement group_id="O2" value="0.065" spread="0.3347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="2.800"/>
                    <measurement group_id="O2" value="0.88" spread="1.560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="1.297"/>
                    <measurement group_id="O2" value="0.83" spread="1.390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.530" spread="1.0830"/>
                    <measurement group_id="O2" value="-0.192" spread="0.8124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.464" spread="1.1979"/>
                    <measurement group_id="O2" value="0.111" spread="1.2147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Number of Participants Meeting Criteria of Potential Clinical Importance for Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), and Heart Rate (HR) at Any Visit Post-Baseline</title>
        <description>Baseline was the Day 1 pre-dose measurement. Vital signs (SBP, DBP, and HR) were measured at Day 1 (30 minutes [min] and 6 h post-dose), Day 7 (pre-dose), and Day 14 (24 h post-dose). Potential clinical concern range for SBP was &lt;85 millimeters of mercury (mmHg) (low) and &gt;160 mmHg (high), for DBP &lt;45 mmHg (low) and &gt;100 mmHg (high) and for HR &lt;40 bpm and &gt;110 bpm. All measurements were obtained in supine position, after a 5-minute rest. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Day 1, Day 7, and Day 14</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Participants received 2 inhalations of matching placebo once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part A: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 micrograms (µg) (2 inhalations of 500 µg each from a single device) administered as a dry powder inhalation, once daily for 14 consecutive days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Number of Participants Meeting Criteria of Potential Clinical Importance for Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), and Heart Rate (HR) at Any Visit Post-Baseline</title>
          <description>Baseline was the Day 1 pre-dose measurement. Vital signs (SBP, DBP, and HR) were measured at Day 1 (30 minutes [min] and 6 h post-dose), Day 7 (pre-dose), and Day 14 (24 h post-dose). Potential clinical concern range for SBP was &lt;85 millimeters of mercury (mmHg) (low) and &gt;160 mmHg (high), for DBP &lt;45 mmHg (low) and &gt;100 mmHg (high) and for HR &lt;40 bpm and &gt;110 bpm. All measurements were obtained in supine position, after a 5-minute rest. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Number of Participants With Normal and Abnormal (Clinically Significant or Not Clinically Significant) Findings in 12-lead Electrocardiogram (ECG) at Any Visit Post-Baseline</title>
        <description>Baseline was the Day 1 (pre-dose) measurement. Single 12-lead ECGs were obtained using an ECG machine that automatically calculates the HR and measures PR, QRS, QT, and corrected QT intervals. Clinical significance was judged by the investigator. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Day 1, Day 7, and Day 14</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Participants received 2 inhalations of matching placebo once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part A: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 micrograms (µg) (2 inhalations of 500 µg each from a single device) administered as a dry powder inhalation, once daily for 14 consecutive days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Number of Participants With Normal and Abnormal (Clinically Significant or Not Clinically Significant) Findings in 12-lead Electrocardiogram (ECG) at Any Visit Post-Baseline</title>
          <description>Baseline was the Day 1 (pre-dose) measurement. Single 12-lead ECGs were obtained using an ECG machine that automatically calculates the HR and measures PR, QRS, QT, and corrected QT intervals. Clinical significance was judged by the investigator. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal - not clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal - clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Change From Baseline in Forced Expiratory Volume in One Second (FEV1) and Forced Vital Capacity (FVC) at the Indicated Time Points</title>
        <description>Baseline is Day 1 pre-dose. FEV1 and FVC are measures of lung function. FEV1 is defined as the maximal amount of air that can be forcefully exhaled in one second. FVC is defined as the maximum amount of air that can be forcibly blown out after a maximum inspiration. FEV1 and FVC measurements were repeated until three technically acceptable measurements (within 150 milliliters of each other) had been made. Only the best of three measurements were recorded. Baseline was the maximum of the planned pre-dose measurements on Day 1. Change from Baseline at any post-dose time point was calculated as the post-dose value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Baseline (Day 1 [pre-dose]), Day 1 (1 h post-dose), Day 7 (pre-dose and 1 h post-dose), and Day 14 (24 h post-dose)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Participants received 2 inhalations of matching placebo once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part A: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 micrograms (µg) (2 inhalations of 500 µg each from a single device) administered as a dry powder inhalation, once daily for 14 consecutive days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Forced Expiratory Volume in One Second (FEV1) and Forced Vital Capacity (FVC) at the Indicated Time Points</title>
          <description>Baseline is Day 1 pre-dose. FEV1 and FVC are measures of lung function. FEV1 is defined as the maximal amount of air that can be forcefully exhaled in one second. FVC is defined as the maximum amount of air that can be forcibly blown out after a maximum inspiration. FEV1 and FVC measurements were repeated until three technically acceptable measurements (within 150 milliliters of each other) had been made. Only the best of three measurements were recorded. Baseline was the maximum of the planned pre-dose measurements on Day 1. Change from Baseline at any post-dose time point was calculated as the post-dose value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FEV1, Day 1, 1 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="-0.01" upper_limit="0.30"/>
                    <measurement group_id="O2" value="0.10" lower_limit="0.02" upper_limit="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, Day 7/8, Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="-0.09" upper_limit="0.15"/>
                    <measurement group_id="O2" value="-0.04" lower_limit="-0.13" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, Day 7/8, 1 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" lower_limit="0.15" upper_limit="0.39"/>
                    <measurement group_id="O2" value="0.18" lower_limit="0.10" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" lower_limit="-0.09" upper_limit="0.06"/>
                    <measurement group_id="O2" value="0.01" lower_limit="-0.07" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, Day 1, 1 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" lower_limit="-0.13" upper_limit="0.47"/>
                    <measurement group_id="O2" value="0.16" lower_limit="0.01" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, Day 7/8, Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" lower_limit="-0.23" upper_limit="0.26"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.12" upper_limit="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, Day 7/8, 1 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" lower_limit="0.09" upper_limit="0.58"/>
                    <measurement group_id="O2" value="0.22" lower_limit="0.09" upper_limit="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" lower_limit="-0.30" upper_limit="0.22"/>
                    <measurement group_id="O2" value="0.10" lower_limit="-0.07" upper_limit="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Adjusted Median Response of Cytokine (Interleukin 6 [IL6], Interleukin 8 [IL8], Tumor Necrosis Factor Alpha [TNFalpha]) Concentrations in Induced Sputum, on Day 7 and Day 14</title>
        <description>This outcome measure was used to estimate the inhibition levels of various doses of GSK2269557 by analyzing inflammatory cytokines IL6, IL8, and TNF alpha using Bayesian methods of statistical analysis, using non-informative prior distributions for all modeling parameters. Posterior medians (adjusted median response) and 95% credible intervals are reported here as medians and 95% confidence intervals respectively. 95% credible interval is reported as 2-sided 95% confidence in the statistical analyses. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Day 7 (pre-dose) and Day 14 (24 h post-dose)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Participants received four inhalations of matching placebo (from four inhalation devices) once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK2269577 100 µg</title>
            <description>Participants received repeat doses of GSK2269557 100 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK2269577 200 µg</title>
            <description>Participants received repeat doses of GSK2269557 200 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK2269577 500 µg</title>
            <description>Participants received repeat doses of GSK2269557 500 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK2269577 700 µg</title>
            <description>Participants received repeat doses of GSK2269557 700 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 100 µg, 500 µg, or placebo.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O7">
            <title>Part B: GSK2269577 2000 µg</title>
            <description>Participants received repeat doses of GSK2269557 2000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 500 µg.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Adjusted Median Response of Cytokine (Interleukin 6 [IL6], Interleukin 8 [IL8], Tumor Necrosis Factor Alpha [TNFalpha]) Concentrations in Induced Sputum, on Day 7 and Day 14</title>
          <description>This outcome measure was used to estimate the inhibition levels of various doses of GSK2269557 by analyzing inflammatory cytokines IL6, IL8, and TNF alpha using Bayesian methods of statistical analysis, using non-informative prior distributions for all modeling parameters. Posterior medians (adjusted median response) and 95% credible intervals are reported here as medians and 95% confidence intervals respectively. 95% credible interval is reported as 2-sided 95% confidence in the statistical analyses. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>Picograms/milliliter (pg/mL)</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL6, Day 7/Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.30" lower_limit="22.07" upper_limit="78.24"/>
                    <measurement group_id="O2" value="37.40" lower_limit="19.64" upper_limit="70.65"/>
                    <measurement group_id="O3" value="28.23" lower_limit="14.80" upper_limit="53.18"/>
                    <measurement group_id="O4" value="30.82" lower_limit="16.23" upper_limit="58.00"/>
                    <measurement group_id="O5" value="52.23" lower_limit="28.73" upper_limit="94.94"/>
                    <measurement group_id="O6" value="31.25" lower_limit="16.01" upper_limit="63.01"/>
                    <measurement group_id="O7" value="33.40" lower_limit="17.52" upper_limit="63.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL6, Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.15" lower_limit="17.72" upper_limit="70.01"/>
                    <measurement group_id="O2" value="37.60" lower_limit="18.71" upper_limit="74.49"/>
                    <measurement group_id="O3" value="28.27" lower_limit="14.10" upper_limit="56.22"/>
                    <measurement group_id="O4" value="22.68" lower_limit="11.32" upper_limit="45.13"/>
                    <measurement group_id="O5" value="35.19" lower_limit="18.32" upper_limit="66.93"/>
                    <measurement group_id="O6" value="42.56" lower_limit="20.57" upper_limit="90.25"/>
                    <measurement group_id="O7" value="41.52" lower_limit="20.62" upper_limit="82.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL8, Day 7/Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2633.21" lower_limit="1401.19" upper_limit="4879.27"/>
                    <measurement group_id="O2" value="2118.15" lower_limit="1157.33" upper_limit="3866.74"/>
                    <measurement group_id="O3" value="1860.78" lower_limit="995.35" upper_limit="3499.61"/>
                    <measurement group_id="O4" value="1523.63" lower_limit="834.99" upper_limit="2745.90"/>
                    <measurement group_id="O5" value="2650.13" lower_limit="1535.07" upper_limit="4634.07"/>
                    <measurement group_id="O6" value="2636.08" lower_limit="1412.65" upper_limit="4978.59"/>
                    <measurement group_id="O7" value="2279.48" lower_limit="1205.35" upper_limit="4210.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL8, Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2942.28" lower_limit="1375.08" upper_limit="6216.67"/>
                    <measurement group_id="O2" value="2664.75" lower_limit="1269.52" upper_limit="5544.49"/>
                    <measurement group_id="O3" value="1879.92" lower_limit="876.50" upper_limit="4056.53"/>
                    <measurement group_id="O4" value="1619.12" lower_limit="778.39" upper_limit="3309.81"/>
                    <measurement group_id="O5" value="1356.35" lower_limit="696.37" upper_limit="2645.82"/>
                    <measurement group_id="O6" value="2394.65" lower_limit="1125.17" upper_limit="5196.20"/>
                    <measurement group_id="O7" value="2170.41" lower_limit="1010.85" upper_limit="4582.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFalpha, Day 7/Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35" lower_limit="1.22" upper_limit="8.98"/>
                    <measurement group_id="O2" value="1.55" lower_limit="0.57" upper_limit="4.33"/>
                    <measurement group_id="O3" value="1.16" lower_limit="0.42" upper_limit="3.25"/>
                    <measurement group_id="O4" value="1.54" lower_limit="0.57" upper_limit="4.19"/>
                    <measurement group_id="O5" value="7.32" lower_limit="3.02" upper_limit="17.85"/>
                    <measurement group_id="O6" value="3.68" lower_limit="1.26" upper_limit="10.51"/>
                    <measurement group_id="O7" value="2.62" lower_limit="0.94" upper_limit="7.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFalpha, Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" lower_limit="1.26" upper_limit="6.54"/>
                    <measurement group_id="O2" value="3.02" lower_limit="1.33" upper_limit="7.00"/>
                    <measurement group_id="O3" value="1.25" lower_limit="0.55" upper_limit="2.90"/>
                    <measurement group_id="O4" value="1.26" lower_limit="0.55" upper_limit="2.87"/>
                    <measurement group_id="O5" value="3.99" lower_limit="1.86" upper_limit="8.50"/>
                    <measurement group_id="O6" value="3.00" lower_limit="1.34" upper_limit="6.75"/>
                    <measurement group_id="O7" value="1.53" lower_limit="0.66" upper_limit="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.599</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 7</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>2.07</ci_upper_limit>
            <estimate_desc>Comparison of IL6 concentrations at Day 7. This is the baseline corrected ratio of 100ug/placebo for day 7.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.442</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 14</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>2.59</ci_upper_limit>
            <estimate_desc>Comparison of IL6 concentrations at Day 14. This is the baseline corrected ratio of 100ug/placebo for day 14.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.823</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 7</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
            <estimate_desc>Comparison of IL6 concentrations at Day 7. This is the baseline corrected ratio of 200ug/placebo for day 7.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.690</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 14</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>1.97</ci_upper_limit>
            <estimate_desc>Comparison of IL6 concentrations at Day 14. This is the baseline corrected ratio of 200ug/placebo for day 14.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.764</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 7</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>1.71</ci_upper_limit>
            <estimate_desc>Comparison of IL6 concentrations at Day 7. This is the baseline corrected ratio of 500ug/placebo for day 7.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.841</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 14</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
            <estimate_desc>Comparison of IL6 concentrations at Day 14. This is the baseline corrected ratio of 500ug/placebo for day 14.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.702</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 7</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
            <estimate_desc>Comparison of IL8 concentrations at Day 7.This is the baseline corrected ratio of 100ug/placebo for day 7.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.578</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 14</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>2.47</ci_upper_limit>
            <estimate_desc>Comparison of IL8 concentrations at Day 14. This is the baseline corrected ratio of 100ug/placebo for day 14.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.783</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 7</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>1.70</ci_upper_limit>
            <estimate_desc>Comparison of IL8 concentrations at Day 7. This is the baseline corrected ratio of 200ug/placebo for day 7.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.797</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 14</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>1.87</ci_upper_limit>
            <estimate_desc>Comparison of IL8 concentrations at Day 14. This is the baseline corrected ratio of 200ug/placebo for day 14.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.919</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 7</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
            <estimate_desc>Comparison of IL8 concentrations at Day 7. This is the baseline corrected ratio of 500ug/placebo for day 7.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.892</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 14</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.21</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
            <estimate_desc>Comparison of IL8 concentrations at Day 14. This is the baseline corrected ratio of 500ug/placebo for day 14.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.860</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 7</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.11</ci_lower_limit>
            <ci_upper_limit>1.93</ci_upper_limit>
            <estimate_desc>Comparison of TNFalpha concentrations at Day 7. This is the baseline corrected ratio of 100ug/placebo for day 7.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.463</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 14</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>2.86</ci_upper_limit>
            <estimate_desc>Comparison of TNFalpha concentrations at Day 14. This is the baseline corrected ratio of 100ug/placebo for day 14.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.932</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 7</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
            <estimate_desc>Comparison of TNFalpha concentrations at Day 7. This is the baseline corrected ratio of 200ug/placebo for day 7.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.952</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 14</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>Comparison of TNFalpha concentrations at Day 14. This is the baseline corrected ratio of 200ug/placebo for day 14.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.873</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 7</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
            <estimate_desc>Comparison of TNFalpha concentrations at Day 7. This is the baseline corrected ratio of 500ug/placebo for day 7.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.953</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 14</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>Comparison of TNFalpha concentrations at Day 14. This is the baseline corrected ratio of 500ug/placebo for day 14.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.281</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 7</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio9</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>2.82</ci_upper_limit>
            <estimate_desc>Comparison of IL6 concentrations at Day 7. This is the baseline corrected ratio of 700ug/placebo for day 7.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.500</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 14</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>2.35</ci_upper_limit>
            <estimate_desc>Comparison of IL6 concentrations at Day 14. This is the baseline corrected ratio of 700ug/placebo for day 14.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.744</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 7</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>1.77</ci_upper_limit>
            <estimate_desc>Comparison of IL6 concentrations at Day 7. This is the baseline corrected ratio of 1000ug/placebo for day 7.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.334</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 14</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>3.04</ci_upper_limit>
            <estimate_desc>Comparison of IL6 concentrations at Day 14. This is the baseline corrected ratio of 1000ug/placebo for day 14.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.698</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 7</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>1.85</ci_upper_limit>
            <estimate_desc>Comparison of IL6 concentrations at Day 7. This is the baseline corrected ratio of 2000ug/placebo for day 7.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.353</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 14</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>2.88</ci_upper_limit>
            <estimate_desc>Comparison of IL6 concentrations at Day 14. This is the baseline corrected ratio of 2000ug/placebo for day 14.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.489</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 7</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio9</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>2.26</ci_upper_limit>
            <estimate_desc>Comparison of IL8 concentrations at Day 7. This is the baseline corrected ratio of 700ug/placebo for day 7.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.940</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 14</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>Comparison of IL8 concentrations at Day 14. This is the baseline corrected ratio of 700ug/placebo for day 14.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.495</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 7</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>2.40</ci_upper_limit>
            <estimate_desc>Comparison of IL8 concentrations at Day 7. This is the baseline corrected ratio of 1000ug/placebo for day 7.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.647</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 14</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>2.37</ci_upper_limit>
            <estimate_desc>Comparison of IL8 concentrations at Day 14. This is the baseline corrected ratio of 1000ug/placebo for day 14.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.646</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 7</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>1.86</ci_upper_limit>
            <estimate_desc>Comparison of IL8 concentrations at Day 7. This is the baseline corrected ratio of 2000ug/placebo for day 7.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.741</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 14</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>1.90</ci_upper_limit>
            <estimate_desc>Comparison of IL8 concentrations at Day 14. This is the baseline corrected ratio of 2000ug/placebo for day 14.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.109</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 7</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio9</param_type>
            <param_value>2.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>7.95</ci_upper_limit>
            <estimate_desc>Comparison of TNFalpha concentrations at Day 7. This is the baseline corrected ratio of 700ug/placebo for day 7.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.240</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 14</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>1.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>3.45</ci_upper_limit>
            <estimate_desc>Comparison of TNFalpha concentrations at Day 14. This is the baseline corrected ratio of 700ug/placebo for day 14.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.447</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 7</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>4.44</ci_upper_limit>
            <estimate_desc>Comparison of TNFalpha concentrations at Day 7. This is the baseline corrected ratio of 1000ug/placebo for day 7.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.472</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 14</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>2.74</ci_upper_limit>
            <estimate_desc>Comparison of TNFalpha concentrations at Day 14. This is the baseline corrected ratio of 1000ug/placebo for day 14.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.698</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 7</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.21</ci_lower_limit>
            <ci_upper_limit>2.90</ci_upper_limit>
            <estimate_desc>Comparison of TNFalpha concentrations at Day 7. This is the baseline corrected ratio of 2000ug/placebo for day 7.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.911</p_value>
            <p_value_desc>Posterior Probability the True Treatment Ratio &lt;1 for Day 14</p_value_desc>
            <method>Bayesian repeated measures</method>
            <param_type>Adjusted Median Ratio</param_type>
            <param_value>0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.21</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
            <estimate_desc>Comparison of TNFalpha concentrations at Day 14. This is the baseline corrected ratio of 2000ug/placebo for day 14.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Day 1 Plasma Concentration of GSK2269577 up to 6 Hours Post Dose</title>
        <description>A 2 mL blood sample for pharmacokinetic (PK) analysis was collected at each of the indicated time point. Only those participants who were available at the indicated time points were analyzed (represented by n=X in the category titles). A value of NA indicates that the geometric mean or 95% confidence interval is not available.</description>
        <time_frame>Day 1 (Pre-dose, 5 min, 30 min, 1, 2, 4 &amp; 6 hours post-dose)</time_frame>
        <population>PK Population: participants in the Safety Population for whom a PK sample was obtained and analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 micrograms (µg) (2 inhalations of 500 µg each from a single device) administered as a dry powder inhalation, once daily for 14 consecutive days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Day 1 Plasma Concentration of GSK2269577 up to 6 Hours Post Dose</title>
          <description>A 2 mL blood sample for pharmacokinetic (PK) analysis was collected at each of the indicated time point. Only those participants who were available at the indicated time points were analyzed (represented by n=X in the category titles). A value of NA indicates that the geometric mean or 95% confidence interval is not available.</description>
          <population>PK Population: participants in the Safety Population for whom a PK sample was obtained and analyzed.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose; n=0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">A value of NA indicates that the geometric mean or 95% confidence interval is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 min; n=21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="386.2" lower_limit="287.5" upper_limit="518.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min; n=21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="337.2" lower_limit="274.6" upper_limit="414.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h; n=21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379.1" lower_limit="320.2" upper_limit="448.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h; n=21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="531.1" lower_limit="448.2" upper_limit="629.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h; n=21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="419.5" lower_limit="357.6" upper_limit="492.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 h; n=21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="334.4" lower_limit="287.0" upper_limit="389.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Day 1 Plasma Concentration of GSK2269577 up to 6 Hours Post Dose</title>
        <description>A 2 mL blood sample for pharmacokinetic (PK) analysis was collected at each of the indicated time point. Concentration measurements were log-transformed. Only those participants who were available at the indicated time points were analyzed (represented by n=X,X in the category titles). A value of NA indicates that the geometric mean or 95% confidence interval is not available.</description>
        <time_frame>Pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, and 6 h post-dose on Day 1</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: GSK2269577 100 µg</title>
            <description>Participants received repeat doses of GSK2269557 100 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK2269577 200 µg</title>
            <description>Participants received repeat doses of GSK2269557 200 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK2269577 500 µg</title>
            <description>Participants received repeat doses of GSK2269557 500 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK2269577 700 µg</title>
            <description>Participants received repeat doses of GSK2269557 700 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 100 µg, 500 µg, or placebo.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK2269577 2000 µg</title>
            <description>Participants received repeat doses of GSK2269557 2000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 500 µg.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Day 1 Plasma Concentration of GSK2269577 up to 6 Hours Post Dose</title>
          <description>A 2 mL blood sample for pharmacokinetic (PK) analysis was collected at each of the indicated time point. Concentration measurements were log-transformed. Only those participants who were available at the indicated time points were analyzed (represented by n=X,X in the category titles). A value of NA indicates that the geometric mean or 95% confidence interval is not available.</description>
          <population>PK Population</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose; n=0,0,0,0,0,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">A value of NA indicates that the geometric mean or 95% confidence interval is not available.</measurement>
                    <measurement group_id="O2" value="NA">A value of NA indicates that the geometric mean or 95% confidence interval is not available.</measurement>
                    <measurement group_id="O3" value="NA">A value of NA indicates that the geometric mean or 95% confidence interval is not available.</measurement>
                    <measurement group_id="O4" value="NA">A value of NA indicates that the geometric mean or 95% confidence interval is not available.</measurement>
                    <measurement group_id="O5" value="NA">A value of NA indicates that the geometric mean or 95% confidence interval is not available.</measurement>
                    <measurement group_id="O6" value="NA">A value of NA indicates that the geometric mean or 95% confidence interval is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 min; n=5,5,5,6,5,5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3" lower_limit="33.7" upper_limit="90.7"/>
                    <measurement group_id="O2" value="80.4" lower_limit="38.4" upper_limit="168.2"/>
                    <measurement group_id="O3" value="173.1" lower_limit="88.4" upper_limit="339.0"/>
                    <measurement group_id="O4" value="466.6" lower_limit="147.3" upper_limit="1478.0"/>
                    <measurement group_id="O5" value="853.4" lower_limit="380.2" upper_limit="1915.6"/>
                    <measurement group_id="O6" value="982.9" lower_limit="311.1" upper_limit="3105.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min; n=5,5,5,6,5,5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7" lower_limit="36.2" upper_limit="74.1"/>
                    <measurement group_id="O2" value="73.8" lower_limit="41.6" upper_limit="130.8"/>
                    <measurement group_id="O3" value="203" lower_limit="111.2" upper_limit="370.5"/>
                    <measurement group_id="O4" value="402.3" lower_limit="218.0" upper_limit="742.5"/>
                    <measurement group_id="O5" value="556.9" lower_limit="384.8" upper_limit="806.0"/>
                    <measurement group_id="O6" value="1011.6" lower_limit="757.1" upper_limit="1351.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h; n=5,5,5,6,5,5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.3" lower_limit="45.7" upper_limit="82.3"/>
                    <measurement group_id="O2" value="77.2" lower_limit="44.1" upper_limit="135.2"/>
                    <measurement group_id="O3" value="253.2" lower_limit="155.0" upper_limit="413.8"/>
                    <measurement group_id="O4" value="429.1" lower_limit="294.2" upper_limit="626.0"/>
                    <measurement group_id="O5" value="599.7" lower_limit="370.5" upper_limit="970.7"/>
                    <measurement group_id="O6" value="1203.3" lower_limit="799.1" upper_limit="1812.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h; n=5,5,5,6,5,5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.6" lower_limit="44.8" upper_limit="81.9"/>
                    <measurement group_id="O2" value="88.8" lower_limit="60.2" upper_limit="130.9"/>
                    <measurement group_id="O3" value="300.9" lower_limit="173.7" upper_limit="521.1"/>
                    <measurement group_id="O4" value="556.7" lower_limit="372.4" upper_limit="832.3"/>
                    <measurement group_id="O5" value="672.3" lower_limit="434.0" upper_limit="1041.5"/>
                    <measurement group_id="O6" value="1402" lower_limit="892.8" upper_limit="2201.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h; n=5,5,5,6,5,5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0" lower_limit="33.1" upper_limit="61.2"/>
                    <measurement group_id="O2" value="73.4" lower_limit="60.5" upper_limit="89.1"/>
                    <measurement group_id="O3" value="251" lower_limit="146.0" upper_limit="431.6"/>
                    <measurement group_id="O4" value="391.6" lower_limit="303.3" upper_limit="505.5"/>
                    <measurement group_id="O5" value="468.7" lower_limit="305.5" upper_limit="719.2"/>
                    <measurement group_id="O6" value="1098.5" lower_limit="781.9" upper_limit="1543.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 h; n=5,5,5,6,5,5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" lower_limit="29.7" upper_limit="49.5"/>
                    <measurement group_id="O2" value="63.8" lower_limit="50.7" upper_limit="80.3"/>
                    <measurement group_id="O3" value="201.5" lower_limit="128.3" upper_limit="316.6"/>
                    <measurement group_id="O4" value="294.6" lower_limit="222.3" upper_limit="390.4"/>
                    <measurement group_id="O5" value="466.5" lower_limit="273.1" upper_limit="796.6"/>
                    <measurement group_id="O6" value="900.8" lower_limit="723.8" upper_limit="1121.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Maximum Observed Plasma Concentration (Cmax) of GSK2269577 on Day 7</title>
        <description>Blood samples were collected to determine the plasma concentrations of GSK2269577 immediately after dosing on Day 7. Day 7 sampling could be done on Day 7 or Day 8.</description>
        <time_frame>Day 7 immediately after dosing</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 micrograms (µg) (2 inhalations of 500 µg each from a single device) administered as a dry powder inhalation, once daily for 14 consecutive days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Maximum Observed Plasma Concentration (Cmax) of GSK2269577 on Day 7</title>
          <description>Blood samples were collected to determine the plasma concentrations of GSK2269577 immediately after dosing on Day 7. Day 7 sampling could be done on Day 7 or Day 8.</description>
          <population>PK Population</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1109.1" lower_limit="901.5" upper_limit="1364.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Maximum Observed Plasma Concentration (Cmax) of GSK2269577 on Day 7</title>
        <description>Blood samples were collected to determine the plasma concentrations of GSK2269577 immediately after dosing on Day 7. Concentration values were log-transformed. Day 7 sampling could be done on Day 7 or Day 8.</description>
        <time_frame>Day 7 immediately after dosing</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: GSK2269577 100 µg</title>
            <description>Participants received repeat doses of GSK2269557 100 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK2269577 200 µg</title>
            <description>Participants received repeat doses of GSK2269557 200 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK2269577 500 µg</title>
            <description>Participants received repeat doses of GSK2269557 500 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK2269577 700 µg</title>
            <description>Participants received repeat doses of GSK2269557 700 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 100 µg, 500 µg, or placebo.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK2269577 2000 µg</title>
            <description>Participants received repeat doses of GSK2269557 2000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 500 µg.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Maximum Observed Plasma Concentration (Cmax) of GSK2269577 on Day 7</title>
          <description>Blood samples were collected to determine the plasma concentrations of GSK2269577 immediately after dosing on Day 7. Concentration values were log-transformed. Day 7 sampling could be done on Day 7 or Day 8.</description>
          <population>PK Population</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.6" lower_limit="62.6" upper_limit="191.8"/>
                    <measurement group_id="O2" value="203.4" lower_limit="140.3" upper_limit="294.8"/>
                    <measurement group_id="O3" value="511.8" lower_limit="233.2" upper_limit="1123.3"/>
                    <measurement group_id="O4" value="1022.2" lower_limit="623.7" upper_limit="1675.2"/>
                    <measurement group_id="O5" value="1655.1" lower_limit="803.2" upper_limit="3410.4"/>
                    <measurement group_id="O6" value="2923.4" lower_limit="1769.4" upper_limit="4830.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Trough Concentration (Ctau) of GSK2269577 on Day 7 and Day 15</title>
        <description>Blood samples were collected to determine the (trough) plasma concentration of GSK2269577 on Day 7 (pre-dose) and Day 15 (24 hours after dosing on Day 14). Day 7 assessments could be done either on Day 7 or on Day 8.</description>
        <time_frame>Day 7 and Day 15</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 micrograms (µg) (2 inhalations of 500 µg each from a single device) administered as a dry powder inhalation, once daily for 14 consecutive days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Trough Concentration (Ctau) of GSK2269577 on Day 7 and Day 15</title>
          <description>Blood samples were collected to determine the (trough) plasma concentration of GSK2269577 on Day 7 (pre-dose) and Day 15 (24 hours after dosing on Day 14). Day 7 assessments could be done either on Day 7 or on Day 8.</description>
          <population>PK Population</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7/Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="604.1" lower_limit="496.6" upper_limit="735.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="711.2" lower_limit="561.8" upper_limit="900.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Trough Concentration (Ctau) of GSK2269577 on Day 7 and Day 15</title>
        <description>Blood samples were collected to determine the (trough) plasma concentration of GSK2269577 on Day 7 (pre-dose) and Day 15 (24 hours after dosing on Day 14). Day 7 assessments could be done either on Day 7 or on Day 8.</description>
        <time_frame>Day 7 and Day 15</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: GSK2269577 100 µg</title>
            <description>Participants received repeat doses of GSK2269557 100 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK2269577 200 µg</title>
            <description>Participants received repeat doses of GSK2269557 200 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK2269577 500 µg</title>
            <description>Participants received repeat doses of GSK2269557 500 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK2269577 700 µg</title>
            <description>Participants received repeat doses of GSK2269557 700 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 100 µg, 500 µg, or placebo.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK2269577 2000 µg</title>
            <description>Participants received repeat doses of GSK2269557 2000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 500 µg.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Trough Concentration (Ctau) of GSK2269577 on Day 7 and Day 15</title>
          <description>Blood samples were collected to determine the (trough) plasma concentration of GSK2269577 on Day 7 (pre-dose) and Day 15 (24 hours after dosing on Day 14). Day 7 assessments could be done either on Day 7 or on Day 8.</description>
          <population>PK Population</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7/Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3" lower_limit="41.22" upper_limit="74.21"/>
                    <measurement group_id="O2" value="119.17" lower_limit="78.47" upper_limit="180.97"/>
                    <measurement group_id="O3" value="314.38" lower_limit="182.64" upper_limit="541.16"/>
                    <measurement group_id="O4" value="588.09" lower_limit="486.63" upper_limit="710.69"/>
                    <measurement group_id="O5" value="724.33" lower_limit="581.37" upper_limit="902.45"/>
                    <measurement group_id="O6" value="1468.94" lower_limit="1000.50" upper_limit="2156.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.93" lower_limit="48.26" upper_limit="116.33"/>
                    <measurement group_id="O2" value="128.71" lower_limit="92.02" upper_limit="180.03"/>
                    <measurement group_id="O3" value="237.36" lower_limit="66.38" upper_limit="848.74"/>
                    <measurement group_id="O4" value="665.9" lower_limit="497.61" upper_limit="891.10"/>
                    <measurement group_id="O5" value="1218.5" lower_limit="985.88" upper_limit="1506.01"/>
                    <measurement group_id="O6" value="1767.34" lower_limit="1079.72" upper_limit="2892.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Number of Times Rescue Medication Was Used by Participants Daily, During the Treatment Period</title>
        <description>Rescue medication was identified from concomitant medication records and the patient diaries which were provided to the participants to record data throughout the treatment period. Only participants who used rescue medication were analyzed. The value NA indicates that the standard deviation could not be calculated as only one participant was analyzed.</description>
        <time_frame>Day 1 to Day 15</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Participants received four inhalations of matching placebo (from four inhalation devices) once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK2269577 100 µg</title>
            <description>Participants received repeat doses of GSK2269557 100 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK2269577 200 µg</title>
            <description>Participants received repeat doses of GSK2269557 200 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK2269577 500 µg</title>
            <description>Participants received repeat doses of GSK2269557 500 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK2269577 700 µg</title>
            <description>Participants received repeat doses of GSK2269557 700 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 100 µg, 500 µg, or placebo.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O7">
            <title>Part B: GSK2269577 2000 µg</title>
            <description>Participants received repeat doses of GSK2269557 2000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 500 µg.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Number of Times Rescue Medication Was Used by Participants Daily, During the Treatment Period</title>
          <description>Rescue medication was identified from concomitant medication records and the patient diaries which were provided to the participants to record data throughout the treatment period. Only participants who used rescue medication were analyzed. The value NA indicates that the standard deviation could not be calculated as only one participant was analyzed.</description>
          <population>Safety Population</population>
          <units>Number of times</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="0.00"/>
                    <measurement group_id="O2" value="2.3">The value NA indicates that the standard deviation could not be calculated as only one participant was analyzed.</measurement>
                    <measurement group_id="O3" value="2.2">The value NA indicates that the standard deviation could not be calculated as only one participant was analyzed.</measurement>
                    <measurement group_id="O5" value="1.0">The value NA indicates that the standard deviation could not be calculated as only one participant was analyzed.</measurement>
                    <measurement group_id="O6" value="1.4" spread="0.63"/>
                    <measurement group_id="O7" value="1.0">The value NA indicates that the standard deviation could not be calculated as only one participant was analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Number of Participants With at Least One Non-serious Adverse Event (AE), Serious Adverse Event (SAE), or Drug-related Adverse Event</title>
        <description>An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition, associated with liver injury and impaired liver function defined as alanine aminotransferase &gt;=3 x upper limit of normal (ULN), and total bilirubin &gt;=2 x ULN or international normalized ratio &gt;1.5. AEs were classified as potentially drug-related, based on the investigator's judgment. Refer to the general AE/SAE module for a list of AEs and SAEs.</description>
        <time_frame>From the start of study treatment until follow-up (assessed for approximately 19 days)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Participants received four inhalations of matching placebo (from four inhalation devices) once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK2269577 100 µg</title>
            <description>Participants received repeat doses of GSK2269557 100 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK2269577 200 µg</title>
            <description>Participants received repeat doses of GSK2269557 200 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK2269577 500 µg</title>
            <description>Participants received repeat doses of GSK2269557 500 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK2269577 700 µg</title>
            <description>Participants received repeat doses of GSK2269557 700 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 100 µg, 500 µg, or placebo.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O7">
            <title>Part B: GSK2269577 2000 µg</title>
            <description>Participants received repeat doses of GSK2269557 2000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 500 µg.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Number of Participants With at Least One Non-serious Adverse Event (AE), Serious Adverse Event (SAE), or Drug-related Adverse Event</title>
          <description>An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition, associated with liver injury and impaired liver function defined as alanine aminotransferase &gt;=3 x upper limit of normal (ULN), and total bilirubin &gt;=2 x ULN or international normalized ratio &gt;1.5. AEs were classified as potentially drug-related, based on the investigator's judgment. Refer to the general AE/SAE module for a list of AEs and SAEs.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one drug-related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Change From Baseline in Counts of Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets, White Blood Cells (WBC), Total Neutrophils (Total ANC) at the Indicated Time Points</title>
        <description>Blood samples were collected for measurement for the indicated tests. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Participants received four inhalations of matching placebo (from four inhalation devices) once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK2269577 100 µg</title>
            <description>Participants received repeat doses of GSK2269557 100 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK2269577 200 µg</title>
            <description>Participants received repeat doses of GSK2269557 200 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK2269577 500 µg</title>
            <description>Participants received repeat doses of GSK2269557 500 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK2269577 700 µg</title>
            <description>Participants received repeat doses of GSK2269557 700 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 100 µg, 500 µg, or placebo.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O7">
            <title>Part B: GSK2269577 2000 µg</title>
            <description>Participants received repeat doses of GSK2269557 2000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 500 µg.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Counts of Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets, White Blood Cells (WBC), Total Neutrophils (Total ANC) at the Indicated Time Points</title>
          <description>Blood samples were collected for measurement for the indicated tests. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>10^9 cells per liter (GI/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.014" spread="0.0241"/>
                    <measurement group_id="O2" value="-0.002" spread="0.0228"/>
                    <measurement group_id="O3" value="0.01" spread="0.0187"/>
                    <measurement group_id="O4" value="0.004" spread="0.0182"/>
                    <measurement group_id="O5" value="0.007" spread="0.0052"/>
                    <measurement group_id="O6" value="-0.005" spread="0.01"/>
                    <measurement group_id="O7" value="0" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.0167"/>
                    <measurement group_id="O2" value="-0.006" spread="0.0261"/>
                    <measurement group_id="O3" value="0.01" spread="0.0122"/>
                    <measurement group_id="O4" value="-0.002" spread="0.0192"/>
                    <measurement group_id="O5" value="0.007" spread="0.0175"/>
                    <measurement group_id="O6" value="-0.008" spread="0.0189"/>
                    <measurement group_id="O7" value="0.01" spread="0.0122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" spread="0.0576"/>
                    <measurement group_id="O2" value="0.01" spread="0.0485"/>
                    <measurement group_id="O3" value="-0.034" spread="0.0702"/>
                    <measurement group_id="O4" value="-0.026" spread="0.0498"/>
                    <measurement group_id="O5" value="0.022" spread="0.1289"/>
                    <measurement group_id="O6" value="-0.002" spread="0.0287"/>
                    <measurement group_id="O7" value="0.012" spread="0.0438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.046" spread="0.0472"/>
                    <measurement group_id="O2" value="-0.01" spread="0.0292"/>
                    <measurement group_id="O3" value="-0.046" spread="0.0378"/>
                    <measurement group_id="O4" value="-0.054" spread="0.1498"/>
                    <measurement group_id="O5" value="0.025" spread="0.1078"/>
                    <measurement group_id="O6" value="0.023" spread="0.0222"/>
                    <measurement group_id="O7" value="0.022" spread="0.0396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.242" spread="0.4797"/>
                    <measurement group_id="O2" value="-0.178" spread="0.5657"/>
                    <measurement group_id="O3" value="-0.022" spread="0.1326"/>
                    <measurement group_id="O4" value="-0.094" spread="0.3092"/>
                    <measurement group_id="O5" value="0.093" spread="0.2813"/>
                    <measurement group_id="O6" value="-0.118" spread="0.3223"/>
                    <measurement group_id="O7" value="-0.218" spread="0.6236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.4499"/>
                    <measurement group_id="O2" value="-0.264" spread="0.3134"/>
                    <measurement group_id="O3" value="-0.216" spread="0.208"/>
                    <measurement group_id="O4" value="0.092" spread="0.9722"/>
                    <measurement group_id="O5" value="0.21" spread="0.3855"/>
                    <measurement group_id="O6" value="-0.243" spread="0.3054"/>
                    <measurement group_id="O7" value="-0.398" spread="0.736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.062" spread="0.0867"/>
                    <measurement group_id="O2" value="0.05" spread="0.0941"/>
                    <measurement group_id="O3" value="-0.02" spread="0.0806"/>
                    <measurement group_id="O4" value="0.05" spread="0.2108"/>
                    <measurement group_id="O5" value="0.018" spread="0.1209"/>
                    <measurement group_id="O6" value="0.165" spread="0.5166"/>
                    <measurement group_id="O7" value="-0.08" spread="0.1398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.022" spread="0.0676"/>
                    <measurement group_id="O2" value="-0.012" spread="0.0926"/>
                    <measurement group_id="O3" value="-0.036" spread="0.0829"/>
                    <measurement group_id="O4" value="-0.004" spread="0.1313"/>
                    <measurement group_id="O5" value="0.03" spread="0.0699"/>
                    <measurement group_id="O6" value="0.108" spread="0.3437"/>
                    <measurement group_id="O7" value="-0.11" spread="0.0834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.8" spread="14.22"/>
                    <measurement group_id="O2" value="-0.8" spread="18.07"/>
                    <measurement group_id="O3" value="10" spread="24.52"/>
                    <measurement group_id="O4" value="15.6" spread="17.78"/>
                    <measurement group_id="O5" value="11.7" spread="15.41"/>
                    <measurement group_id="O6" value="26.5" spread="32.77"/>
                    <measurement group_id="O7" value="-0.6" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="22.25"/>
                    <measurement group_id="O2" value="-13" spread="26.52"/>
                    <measurement group_id="O3" value="-7.2" spread="20.41"/>
                    <measurement group_id="O4" value="-1.4" spread="44.86"/>
                    <measurement group_id="O5" value="7" spread="19.81"/>
                    <measurement group_id="O6" value="-8.3" spread="51.57"/>
                    <measurement group_id="O7" value="-11.4" spread="29.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.372" spread="1.5852"/>
                    <measurement group_id="O2" value="-0.024" spread="1.1519"/>
                    <measurement group_id="O3" value="0.102" spread="1.1107"/>
                    <measurement group_id="O4" value="0.926" spread="3.1314"/>
                    <measurement group_id="O5" value="0.497" spread="0.8673"/>
                    <measurement group_id="O6" value="0.5" spread="2.676"/>
                    <measurement group_id="O7" value="-0.802" spread="0.7889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="0.5204"/>
                    <measurement group_id="O2" value="-0.864" spread="1.4151"/>
                    <measurement group_id="O3" value="-0.164" spread="0.7907"/>
                    <measurement group_id="O4" value="-0.178" spread="2.2899"/>
                    <measurement group_id="O5" value="0.648" spread="1.143"/>
                    <measurement group_id="O6" value="0.825" spread="1.6016"/>
                    <measurement group_id="O7" value="-1.012" spread="1.3388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ANC; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.164" spread="0.9782"/>
                    <measurement group_id="O2" value="0.09" spread="0.6553"/>
                    <measurement group_id="O3" value="0.17" spread="1.0481"/>
                    <measurement group_id="O4" value="1.018" spread="2.6669"/>
                    <measurement group_id="O5" value="0.335" spread="0.5921"/>
                    <measurement group_id="O6" value="0.448" spread="2.153"/>
                    <measurement group_id="O7" value="-0.51" spread="0.285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ANC; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.4288"/>
                    <measurement group_id="O2" value="-0.538" spread="1.1027"/>
                    <measurement group_id="O3" value="0.134" spread="0.801"/>
                    <measurement group_id="O4" value="-0.18" spread="1.469"/>
                    <measurement group_id="O5" value="0.385" spread="1.2151"/>
                    <measurement group_id="O6" value="0.958" spread="1.8925"/>
                    <measurement group_id="O7" value="-0.51" spread="0.7931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) at the Indicated Time Points</title>
        <description>Blood samples were collected for measurement for the indicated tests. MCHC is one of the red blood cell (RBC) indices. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Participants received four inhalations of matching placebo (from four inhalation devices) once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK2269577 100 µg</title>
            <description>Participants received repeat doses of GSK2269557 100 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK2269577 200 µg</title>
            <description>Participants received repeat doses of GSK2269557 200 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK2269577 500 µg</title>
            <description>Participants received repeat doses of GSK2269557 500 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK2269577 700 µg</title>
            <description>Participants received repeat doses of GSK2269557 700 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 100 µg, 500 µg, or placebo.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O7">
            <title>Part B: GSK2269577 2000 µg</title>
            <description>Participants received repeat doses of GSK2269557 2000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 500 µg.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) at the Indicated Time Points</title>
          <description>Blood samples were collected for measurement for the indicated tests. MCHC is one of the red blood cell (RBC) indices. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="2.55" lower_limit="2.55"/>
                    <measurement group_id="O2" value="0.8" spread="5.76"/>
                    <measurement group_id="O3" value="3.8" spread="6.76"/>
                    <measurement group_id="O4" value="1" spread="4.74"/>
                    <measurement group_id="O5" value="0.3" spread="5.65"/>
                    <measurement group_id="O6" value="6" spread="5.89"/>
                    <measurement group_id="O7" value="1" spread="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="6.14" lower_limit="6.14"/>
                    <measurement group_id="O2" value="-1.2" spread="6.14"/>
                    <measurement group_id="O3" value="-0.6" spread="8.02"/>
                    <measurement group_id="O4" value="-2" spread="6.86"/>
                    <measurement group_id="O5" value="-2.2" spread="2.14"/>
                    <measurement group_id="O6" value="-0.3" spread="4.65"/>
                    <measurement group_id="O7" value="-0.2" spread="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="2.07" lower_limit="2.07"/>
                    <measurement group_id="O2" value="-0.6" spread="8.17"/>
                    <measurement group_id="O3" value="-4.0" spread="7.31"/>
                    <measurement group_id="O4" value="-4.4" spread="9.61"/>
                    <measurement group_id="O5" value="0.5" spread="5.17"/>
                    <measurement group_id="O6" value="3.3" spread="8.18"/>
                    <measurement group_id="O7" value="7.8" spread="10.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="5.07" lower_limit="5.07"/>
                    <measurement group_id="O2" value="-2.6" spread="3.51"/>
                    <measurement group_id="O3" value="-4.4" spread="8.73"/>
                    <measurement group_id="O4" value="3.0" spread="4.00"/>
                    <measurement group_id="O5" value="2.5" spread="3.83"/>
                    <measurement group_id="O6" value="-8.5" spread="7.59"/>
                    <measurement group_id="O7" value="1.6" spread="11.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Change From Baseline in Counts of RBCs and Reticulocytes at the Indicated Time Points</title>
        <description>Blood samples were collected for measurement for the indicated tests. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Participants received four inhalations of matching placebo (from four inhalation devices) once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK2269577 100 µg</title>
            <description>Participants received repeat doses of GSK2269557 100 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK2269577 200 µg</title>
            <description>Participants received repeat doses of GSK2269557 200 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK2269577 500 µg</title>
            <description>Participants received repeat doses of GSK2269557 500 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK2269577 700 µg</title>
            <description>Participants received repeat doses of GSK2269557 700 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 100 µg, 500 µg, or placebo.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O7">
            <title>Part B: GSK2269577 2000 µg</title>
            <description>Participants received repeat doses of GSK2269557 2000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 500 µg.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Counts of RBCs and Reticulocytes at the Indicated Time Points</title>
          <description>Blood samples were collected for measurement for the indicated tests. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>10^12 cells/Liter (TI/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RBC; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.076" spread="0.1148"/>
                    <measurement group_id="O2" value="0.036" spread="0.1549"/>
                    <measurement group_id="O3" value="0.18" spread="0.2703"/>
                    <measurement group_id="O4" value="0.058" spread="0.1314"/>
                    <measurement group_id="O5" value="-0.023" spread="0.1508"/>
                    <measurement group_id="O6" value="0.14" spread="0.0879"/>
                    <measurement group_id="O7" value="-0.058" spread="0.1252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.1891"/>
                    <measurement group_id="O2" value="-0.038" spread="0.1663"/>
                    <measurement group_id="O3" value="0.034" spread="0.1785"/>
                    <measurement group_id="O4" value="-0.07" spread="0.1815"/>
                    <measurement group_id="O5" value="-0.083" spread="0.0958"/>
                    <measurement group_id="O6" value="0.042" spread="0.1031"/>
                    <measurement group_id="O7" value="-0.084" spread="0.1496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00064" spread="0.01328"/>
                    <measurement group_id="O2" value="0.00714" spread="0.020838"/>
                    <measurement group_id="O3" value="0.01298" spread="0.011129"/>
                    <measurement group_id="O4" value="0.01258" spread="0.014565"/>
                    <measurement group_id="O5" value="0.00397" spread="0.008856"/>
                    <measurement group_id="O6" value="0.00882" spread="0.018576"/>
                    <measurement group_id="O7" value="0.01792" spread="0.012824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0034" spread="0.014934"/>
                    <measurement group_id="O2" value="0.0006" spread="0.010183"/>
                    <measurement group_id="O3" value="0.01032" spread="0.015404"/>
                    <measurement group_id="O4" value="0.0156" spread="0.013092"/>
                    <measurement group_id="O5" value="-0.00172" spread="0.005382"/>
                    <measurement group_id="O6" value="-0.01063" spread="0.018329"/>
                    <measurement group_id="O7" value="0.00884" spread="0.015546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Change From Baseline in Hematocrit at the Indicated Time Points</title>
        <description>Blood samples were collected for measurement for the indicated tests. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Participants received four inhalations of matching placebo (from four inhalation devices) once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK2269577 100 µg</title>
            <description>Participants received repeat doses of GSK2269557 100 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK2269577 200 µg</title>
            <description>Participants received repeat doses of GSK2269557 200 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK2269577 500 µg</title>
            <description>Participants received repeat doses of GSK2269557 500 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK2269577 700 µg</title>
            <description>Participants received repeat doses of GSK2269557 700 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 100 µg, 500 µg, or placebo.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O7">
            <title>Part B: GSK2269577 2000 µg</title>
            <description>Participants received repeat doses of GSK2269557 2000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 500 µg.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Hematocrit at the Indicated Time Points</title>
          <description>Blood samples were collected for measurement for the indicated tests. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.012" spread="0.0084"/>
                    <measurement group_id="O2" value="0.004" spread="0.0182"/>
                    <measurement group_id="O3" value="0.018" spread="0.0259"/>
                    <measurement group_id="O4" value="0.01" spread="0.01"/>
                    <measurement group_id="O5" value="0" spread="0.0141"/>
                    <measurement group_id="O6" value="0.015" spread="0.0058"/>
                    <measurement group_id="O7" value="-0.010" spread="0.0235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008" spread="0.0217"/>
                    <measurement group_id="O2" value="0" spread="0.0212"/>
                    <measurement group_id="O3" value="0.006" spread="0.0152"/>
                    <measurement group_id="O4" value="-0.012" spread="0.0217"/>
                    <measurement group_id="O5" value="-0.01" spread="0.0063"/>
                    <measurement group_id="O6" value="0.01" spread="0.0082"/>
                    <measurement group_id="O7" value="-0.004" spread="0.0207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at the Indicated Time Points</title>
        <description>Blood samples were collected for measurement for the indicated tests. MCH is one of the red blood cell indices. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Participants received four inhalations of matching placebo (from four inhalation devices) once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK2269577 100 µg</title>
            <description>Participants received repeat doses of GSK2269557 100 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK2269577 200 µg</title>
            <description>Participants received repeat doses of GSK2269557 200 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK2269577 500 µg</title>
            <description>Participants received repeat doses of GSK2269557 500 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK2269577 700 µg</title>
            <description>Participants received repeat doses of GSK2269557 700 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 100 µg, 500 µg, or placebo.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O7">
            <title>Part B: GSK2269577 2000 µg</title>
            <description>Participants received repeat doses of GSK2269557 2000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 500 µg.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at the Indicated Time Points</title>
          <description>Blood samples were collected for measurement for the indicated tests. MCH is one of the red blood cell indices. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>pg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.415"/>
                    <measurement group_id="O2" value="-0.06" spread="0.397"/>
                    <measurement group_id="O3" value="-0.36" spread="0.351"/>
                    <measurement group_id="O4" value="-0.08" spread="0.669"/>
                    <measurement group_id="O5" value="0.2" spread="0.529"/>
                    <measurement group_id="O6" value="0.35" spread="0.961"/>
                    <measurement group_id="O7" value="0.58" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.626"/>
                    <measurement group_id="O2" value="0.02" spread="0.259"/>
                    <measurement group_id="O3" value="-0.34" spread="0.74"/>
                    <measurement group_id="O4" value="0.12" spread="0.396"/>
                    <measurement group_id="O5" value="0.1" spread="0.363"/>
                    <measurement group_id="O6" value="-0.33" spread="0.754"/>
                    <measurement group_id="O7" value="0.52" spread="0.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Change From Baseline in Mean Corpuscle Volume (MCV) at the Indicated Time Points</title>
        <description>Blood samples were collected for measurement for the indicated tests. MCV is one of the RBC indices. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Participants received four inhalations of matching placebo (from four inhalation devices) once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK2269577 100 µg</title>
            <description>Participants received repeat doses of GSK2269557 100 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK2269577 200 µg</title>
            <description>Participants received repeat doses of GSK2269557 200 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK2269577 500 µg</title>
            <description>Participants received repeat doses of GSK2269557 500 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK2269577 700 µg</title>
            <description>Participants received repeat doses of GSK2269557 700 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 100 µg, 500 µg, or placebo.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O7">
            <title>Part B: GSK2269577 2000 µg</title>
            <description>Participants received repeat doses of GSK2269557 2000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 500 µg.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Mean Corpuscle Volume (MCV) at the Indicated Time Points</title>
          <description>Blood samples were collected for measurement for the indicated tests. MCV is one of the RBC indices. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>fL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MCV; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread="0.706"/>
                    <measurement group_id="O2" value="-0.14" spread="1.794"/>
                    <measurement group_id="O3" value="-0.12" spread="1.708"/>
                    <measurement group_id="O4" value="0.88" spread="1.085"/>
                    <measurement group_id="O5" value="0.42" spread="2.302"/>
                    <measurement group_id="O6" value="0.20" spread="0.583"/>
                    <measurement group_id="O7" value="-0.70" spread="2.719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCV; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="1.537"/>
                    <measurement group_id="O2" value="0.80" spread="1.257"/>
                    <measurement group_id="O3" value="0.26" spread="1.935"/>
                    <measurement group_id="O4" value="-0.62" spread="1.281"/>
                    <measurement group_id="O5" value="-0.53" spread="1.601"/>
                    <measurement group_id="O6" value="1.53" spread="0.699"/>
                    <measurement group_id="O7" value="0.98" spread="3.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Change From Baseline in Albumin and Total Protein at the Indicated Time Points</title>
        <description>Blood samples were collected for measurement for the indicated tests. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Participants received four inhalations of matching placebo (from four inhalation devices) once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK2269577 100 µg</title>
            <description>Participants received repeat doses of GSK2269557 100 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK2269577 200 µg</title>
            <description>Participants received repeat doses of GSK2269557 200 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK2269577 500 µg</title>
            <description>Participants received repeat doses of GSK2269557 500 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK2269577 700 µg</title>
            <description>Participants received repeat doses of GSK2269557 700 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 100 µg, 500 µg, or placebo.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O7">
            <title>Part B: GSK2269577 2000 µg</title>
            <description>Participants received repeat doses of GSK2269557 2000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 500 µg.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Albumin and Total Protein at the Indicated Time Points</title>
          <description>Blood samples were collected for measurement for the indicated tests. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="1.773"/>
                    <measurement group_id="O2" value="1.22" spread="1.571"/>
                    <measurement group_id="O3" value="0.96" spread="3.012"/>
                    <measurement group_id="O4" value="0.88" spread="0.887"/>
                    <measurement group_id="O5" value="-0.6" spread="1.814"/>
                    <measurement group_id="O6" value="1.18" spread="1.069"/>
                    <measurement group_id="O7" value="0.3" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="2.965"/>
                    <measurement group_id="O2" value="0.7" spread="2.134"/>
                    <measurement group_id="O3" value="-0.12" spread="2.538"/>
                    <measurement group_id="O4" value="-1.16" spread="2.157"/>
                    <measurement group_id="O5" value="-1.13" spread="1.365"/>
                    <measurement group_id="O6" value="0.44" spread="1.001"/>
                    <measurement group_id="O7" value="0.26" spread="1.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="2.46"/>
                    <measurement group_id="O2" value="0.72" spread="1.203"/>
                    <measurement group_id="O3" value="2.22" spread="4.953"/>
                    <measurement group_id="O4" value="0.98" spread="2.039"/>
                    <measurement group_id="O5" value="-1.4" spread="2.662"/>
                    <measurement group_id="O6" value="1.78" spread="2.338"/>
                    <measurement group_id="O7" value="1.12" spread="1.571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="3.392"/>
                    <measurement group_id="O2" value="0.96" spread="2.393"/>
                    <measurement group_id="O3" value="-0.16" spread="3.737"/>
                    <measurement group_id="O4" value="-1.96" spread="3.635"/>
                    <measurement group_id="O5" value="-2.13" spread="2.156"/>
                    <measurement group_id="O6" value="0.72" spread="1.154"/>
                    <measurement group_id="O7" value="0.7" spread="2.277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) at the Indicated Time Points</title>
        <description>Blood samples were collected for measurement for the indicated tests. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Participants received four inhalations of matching placebo (from four inhalation devices) once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK2269577 100 µg</title>
            <description>Participants received repeat doses of GSK2269557 100 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK2269577 200 µg</title>
            <description>Participants received repeat doses of GSK2269557 200 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK2269577 500 µg</title>
            <description>Participants received repeat doses of GSK2269557 500 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK2269577 700 µg</title>
            <description>Participants received repeat doses of GSK2269557 700 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 100 µg, 500 µg, or placebo.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O7">
            <title>Part B: GSK2269577 2000 µg</title>
            <description>Participants received repeat doses of GSK2269557 2000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 500 µg.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) at the Indicated Time Points</title>
          <description>Blood samples were collected for measurement for the indicated tests. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>International Units per Liter (IU/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALP; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="5.45"/>
                    <measurement group_id="O2" value="1.62" spread="5.756"/>
                    <measurement group_id="O3" value="1.64" spread="7.946"/>
                    <measurement group_id="O4" value="5.7" spread="9.986"/>
                    <measurement group_id="O5" value="-0.95" spread="7.807"/>
                    <measurement group_id="O6" value="-0.92" spread="22.572"/>
                    <measurement group_id="O7" value="1.66" spread="5.465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="4.503"/>
                    <measurement group_id="O2" value="4.78" spread="7.294"/>
                    <measurement group_id="O3" value="-0.2" spread="6.109"/>
                    <measurement group_id="O4" value="0.26" spread="9.829"/>
                    <measurement group_id="O5" value="-1.1" spread="8.535"/>
                    <measurement group_id="O6" value="-5.34" spread="19.016"/>
                    <measurement group_id="O7" value="5.2" spread="4.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="2.24"/>
                    <measurement group_id="O2" value="3.66" spread="6.057"/>
                    <measurement group_id="O3" value="-2.44" spread="7.23"/>
                    <measurement group_id="O4" value="2.6" spread="4.994"/>
                    <measurement group_id="O5" value="-0.1" spread="2.994"/>
                    <measurement group_id="O6" value="-2.4" spread="5.036"/>
                    <measurement group_id="O7" value="1.42" spread="2.791"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="2.268"/>
                    <measurement group_id="O2" value="2.18" spread="3.17"/>
                    <measurement group_id="O3" value="-2.76" spread="6.176"/>
                    <measurement group_id="O4" value="0.84" spread="5.223"/>
                    <measurement group_id="O5" value="-0.72" spread="4.63"/>
                    <measurement group_id="O6" value="-2.86" spread="5.478"/>
                    <measurement group_id="O7" value="1.58" spread="3.754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="2.464"/>
                    <measurement group_id="O2" value="3.76" spread="11.142"/>
                    <measurement group_id="O3" value="-0.42" spread="3.13"/>
                    <measurement group_id="O4" value="0.26" spread="5.185"/>
                    <measurement group_id="O5" value="-0.22" spread="3.672"/>
                    <measurement group_id="O6" value="-2.56" spread="5.607"/>
                    <measurement group_id="O7" value="3.04" spread="2.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="1.691"/>
                    <measurement group_id="O2" value="0.16" spread="1.673"/>
                    <measurement group_id="O3" value="-2.44" spread="3.443"/>
                    <measurement group_id="O4" value="-1.64" spread="6.027"/>
                    <measurement group_id="O5" value="0.02" spread="3.129"/>
                    <measurement group_id="O6" value="-1.66" spread="4.536"/>
                    <measurement group_id="O7" value="2.66" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="2.119"/>
                    <measurement group_id="O2" value="-0.3" spread="1.856"/>
                    <measurement group_id="O3" value="-0.96" spread="4.556"/>
                    <measurement group_id="O4" value="-0.3" spread="4.471"/>
                    <measurement group_id="O5" value="1.88" spread="4.747"/>
                    <measurement group_id="O6" value="-3.18" spread="9.7"/>
                    <measurement group_id="O7" value="0.74" spread="1.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="0.934"/>
                    <measurement group_id="O2" value="0.1" spread="2.625"/>
                    <measurement group_id="O3" value="-2.64" spread="6.532"/>
                    <measurement group_id="O4" value="-0.72" spread="5.485"/>
                    <measurement group_id="O5" value="1.52" spread="5.783"/>
                    <measurement group_id="O6" value="-6.16" spread="17.113"/>
                    <measurement group_id="O7" value="0.54" spread="1.923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Change From Baseline in Creatinine, Bilirubin, and Total Bilirubin at the Indicated Time Points</title>
        <description>Blood samples were collected for measurement for the indicated tests. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Participants received four inhalations of matching placebo (from four inhalation devices) once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK2269577 100 µg</title>
            <description>Participants received repeat doses of GSK2269557 100 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK2269577 200 µg</title>
            <description>Participants received repeat doses of GSK2269557 200 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK2269577 500 µg</title>
            <description>Participants received repeat doses of GSK2269557 500 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK2269577 700 µg</title>
            <description>Participants received repeat doses of GSK2269557 700 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 100 µg, 500 µg, or placebo.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O7">
            <title>Part B: GSK2269577 2000 µg</title>
            <description>Participants received repeat doses of GSK2269557 2000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 500 µg.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Creatinine, Bilirubin, and Total Bilirubin at the Indicated Time Points</title>
          <description>Blood samples were collected for measurement for the indicated tests. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>Micromoles/Liter (micromol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Direct bilirubin; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.327"/>
                    <measurement group_id="O2" value="0.24" spread="0.493"/>
                    <measurement group_id="O3" value="-0.28" spread="0.881"/>
                    <measurement group_id="O4" value="0.16" spread="0.261"/>
                    <measurement group_id="O5" value="0.23" spread="0.65"/>
                    <measurement group_id="O6" value="-0.18" spread="1.36"/>
                    <measurement group_id="O7" value="-0.32" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.453"/>
                    <measurement group_id="O2" value="-0.02" spread="0.192"/>
                    <measurement group_id="O3" value="-0.58" spread="0.581"/>
                    <measurement group_id="O4" value="0.22" spread="0.409"/>
                    <measurement group_id="O5" value="0.2" spread="0.429"/>
                    <measurement group_id="O6" value="0.02" spread="0.554"/>
                    <measurement group_id="O7" value="-0.14" spread="0.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="2.255"/>
                    <measurement group_id="O2" value="0.56" spread="2.151"/>
                    <measurement group_id="O3" value="-0.7" spread="4.049"/>
                    <measurement group_id="O4" value="0.72" spread="2.196"/>
                    <measurement group_id="O5" value="1.08" spread="2.775"/>
                    <measurement group_id="O6" value="-0.86" spread="1.75"/>
                    <measurement group_id="O7" value="-1.5" spread="1.739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="3.389"/>
                    <measurement group_id="O2" value="0.08" spread="0.87"/>
                    <measurement group_id="O3" value="-2.08" spread="2.387"/>
                    <measurement group_id="O4" value="0.52" spread="2.7"/>
                    <measurement group_id="O5" value="1.22" spread="3.008"/>
                    <measurement group_id="O6" value="0.5" spread="2.804"/>
                    <measurement group_id="O7" value="-1.06" spread="1.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.52" spread="4.533"/>
                    <measurement group_id="O2" value="1.6" spread="3.77"/>
                    <measurement group_id="O3" value="4.38" spread="2.217"/>
                    <measurement group_id="O4" value="-0.3" spread="4.567"/>
                    <measurement group_id="O5" value="0.52" spread="4.397"/>
                    <measurement group_id="O6" value="3.48" spread="3.084"/>
                    <measurement group_id="O7" value="0.76" spread="5.421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="7.276"/>
                    <measurement group_id="O2" value="0.76" spread="3.319"/>
                    <measurement group_id="O3" value="4.84" spread="4.636"/>
                    <measurement group_id="O4" value="-0.46" spread="6.98"/>
                    <measurement group_id="O5" value="2.05" spread="3.17"/>
                    <measurement group_id="O6" value="1.36" spread="2.545"/>
                    <measurement group_id="O7" value="1.42" spread="5.058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Change From Baseline in Calcium, Potassium, Sodium, Glucose, and Blood Urea Nitrogen (BUN) at the Indicated Time Points</title>
        <description>Blood samples were collected for measurement for the indicated tests. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Baseline (Day 1 [pre-dose]), Day 7 (pre-dose), and Day 14 (24 hours [h] post-dose)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Participants received four inhalations of matching placebo (from four inhalation devices) once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK2269577 100 µg</title>
            <description>Participants received repeat doses of GSK2269557 100 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK2269577 200 µg</title>
            <description>Participants received repeat doses of GSK2269557 200 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK2269577 500 µg</title>
            <description>Participants received repeat doses of GSK2269557 500 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK2269577 700 µg</title>
            <description>Participants received repeat doses of GSK2269557 700 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 100 µg, 500 µg, or placebo.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O7">
            <title>Part B: GSK2269577 2000 µg</title>
            <description>Participants received repeat doses of GSK2269557 2000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 500 µg.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Calcium, Potassium, Sodium, Glucose, and Blood Urea Nitrogen (BUN) at the Indicated Time Points</title>
          <description>Blood samples were collected for measurement for the indicated tests. Change from Baseline at any post-dose visit was calculated as the post-dose visit value minus the Baseline value. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>Millimoles per Liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.048" spread="0.0444"/>
                    <measurement group_id="O2" value="0.044" spread="0.0397"/>
                    <measurement group_id="O3" value="0.06" spread="0.0579"/>
                    <measurement group_id="O4" value="0.01" spread="0.0648"/>
                    <measurement group_id="O5" value="-0.008" spread="0.0655"/>
                    <measurement group_id="O6" value="0.066" spread="0.0811"/>
                    <measurement group_id="O7" value="0.044" spread="0.0365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.024" spread="0.0865"/>
                    <measurement group_id="O2" value="-0.012" spread="0.0482"/>
                    <measurement group_id="O3" value="0.05" spread="0.0696"/>
                    <measurement group_id="O4" value="-0.01" spread="0.0758"/>
                    <measurement group_id="O5" value="-0.042" spread="0.0422"/>
                    <measurement group_id="O6" value="0.03" spread="0.0292"/>
                    <measurement group_id="O7" value="0.036" spread="0.0568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.2939"/>
                    <measurement group_id="O2" value="0.054" spread="0.4057"/>
                    <measurement group_id="O3" value="0.05" spread="0.1937"/>
                    <measurement group_id="O4" value="-0.43" spread="1.4084"/>
                    <measurement group_id="O5" value="-0.11" spread="0.5658"/>
                    <measurement group_id="O6" value="0.11" spread="0.4369"/>
                    <measurement group_id="O7" value="-0.246" spread="0.273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.086" spread="0.3743"/>
                    <measurement group_id="O2" value="-0.142" spread="0.3746"/>
                    <measurement group_id="O3" value="0.26" spread="0.5456"/>
                    <measurement group_id="O4" value="0.054" spread="0.2294"/>
                    <measurement group_id="O5" value="-0.34" spread="0.7332"/>
                    <measurement group_id="O6" value="-0.076" spread="0.3518"/>
                    <measurement group_id="O7" value="-0.314" spread="0.3871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.246" spread="0.3088"/>
                    <measurement group_id="O2" value="0.09" spread="0.2793"/>
                    <measurement group_id="O3" value="0.434" spread="0.5451"/>
                    <measurement group_id="O4" value="-0.204" spread="0.2563"/>
                    <measurement group_id="O5" value="0.135" spread="0.3172"/>
                    <measurement group_id="O6" value="0.276" spread="0.3566"/>
                    <measurement group_id="O7" value="0.192" spread="0.4587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.1944"/>
                    <measurement group_id="O2" value="0.12" spread="0.4282"/>
                    <measurement group_id="O3" value="0.336" spread="0.5268"/>
                    <measurement group_id="O4" value="-0.128" spread="0.3241"/>
                    <measurement group_id="O5" value="0.013" spread="0.203"/>
                    <measurement group_id="O6" value="0.14" spread="0.1259"/>
                    <measurement group_id="O7" value="0.072" spread="0.5946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="1.206"/>
                    <measurement group_id="O2" value="0.6" spread="1.626"/>
                    <measurement group_id="O3" value="-0.12" spread="1.714"/>
                    <measurement group_id="O4" value="1.18" spread="1.139"/>
                    <measurement group_id="O5" value="-0.33" spread="2.072"/>
                    <measurement group_id="O6" value="0.7" spread="1.815"/>
                    <measurement group_id="O7" value="-0.84" spread="2.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="1.301"/>
                    <measurement group_id="O2" value="-0.04" spread="3.233"/>
                    <measurement group_id="O3" value="0.58" spread="1.399"/>
                    <measurement group_id="O4" value="0.46" spread="1.447"/>
                    <measurement group_id="O5" value="-0.18" spread="2.515"/>
                    <measurement group_id="O6" value="1.06" spread="1.074"/>
                    <measurement group_id="O7" value="-0.4" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN; Day 7/Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.314" spread="0.7077"/>
                    <measurement group_id="O2" value="-0.504" spread="0.6955"/>
                    <measurement group_id="O3" value="0.342" spread="0.8193"/>
                    <measurement group_id="O4" value="-0.91" spread="1.0653"/>
                    <measurement group_id="O5" value="-0.29" spread="0.4396"/>
                    <measurement group_id="O6" value="-0.244" spread="1.2909"/>
                    <measurement group_id="O7" value="0.162" spread="1.2285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN; Day 14, 24 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.232" spread="0.3592"/>
                    <measurement group_id="O2" value="-0.124" spread="0.7502"/>
                    <measurement group_id="O3" value="0.142" spread="1.0269"/>
                    <measurement group_id="O4" value="-0.906" spread="1.6431"/>
                    <measurement group_id="O5" value="-0.335" spread="0.2793"/>
                    <measurement group_id="O6" value="-0.364" spread="0.8554"/>
                    <measurement group_id="O7" value="0.186" spread="2.0478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Number of Participants Meeting Criteria of Potential Clinical Importance for Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), and Heart Rate (HR) at Any Visit Post-Baseline</title>
        <description>Baseline was the Day 1 pre-dose measurement. Vital signs (SBP, DBP, and HR) were measured at Day 1 (30 minutes [min] and 6 h post-dose), Day 7 (pre-dose), and Day 14 (24 h post-dose). All measurements were obtained in supine position, after a 5-minute rest. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Day 1, Day 7, and Day 14</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Participants received four inhalations of matching placebo (from four inhalation devices) once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK2269577 100 µg</title>
            <description>Participants received repeat doses of GSK2269557 100 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK2269577 200 µg</title>
            <description>Participants received repeat doses of GSK2269557 200 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK2269577 500 µg</title>
            <description>Participants received repeat doses of GSK2269557 500 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK2269577 700 µg</title>
            <description>Participants received repeat doses of GSK2269557 700 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 100 µg, 500 µg, or placebo.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O7">
            <title>Part B: GSK2269577 2000 µg</title>
            <description>Participants received repeat doses of GSK2269557 2000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 500 µg.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Number of Participants Meeting Criteria of Potential Clinical Importance for Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), and Heart Rate (HR) at Any Visit Post-Baseline</title>
          <description>Baseline was the Day 1 pre-dose measurement. Vital signs (SBP, DBP, and HR) were measured at Day 1 (30 minutes [min] and 6 h post-dose), Day 7 (pre-dose), and Day 14 (24 h post-dose). All measurements were obtained in supine position, after a 5-minute rest. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Number of Participants With Normal and Abnormal (Clinically Significant or Not Clinically Significant) Findings in 12-lead Electrocardiogram (ECG) at Any Visit Post-Baseline</title>
        <description>Baseline was the Day 1 (pre-dose) measurement. Single 12-lead ECGs were obtained using an ECG machine that automatically calculates the HR and measures PR, QRS, QT, and corrected QT intervals. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
        <time_frame>Day 1, Day 7, and Day 14</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Participants received four inhalations of matching placebo (from four inhalation devices) once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK2269577 100 µg</title>
            <description>Participants received repeat doses of GSK2269557 100 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK2269577 200 µg</title>
            <description>Participants received repeat doses of GSK2269557 200 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK2269577 500 µg</title>
            <description>Participants received repeat doses of GSK2269557 500 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK2269577 700 µg</title>
            <description>Participants received repeat doses of GSK2269557 700 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 100 µg, 500 µg, or placebo.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O7">
            <title>Part B: GSK2269577 2000 µg</title>
            <description>Participants received repeat doses of GSK2269557 2000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 500 µg.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Number of Participants With Normal and Abnormal (Clinically Significant or Not Clinically Significant) Findings in 12-lead Electrocardiogram (ECG) at Any Visit Post-Baseline</title>
          <description>Baseline was the Day 1 (pre-dose) measurement. Single 12-lead ECGs were obtained using an ECG machine that automatically calculates the HR and measures PR, QRS, QT, and corrected QT intervals. Day 7 assessments could be conducted on Day 7 or Day 8.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal - not clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal - clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Forced Expiratory Volume in One Second (FEV1) and Forced Vital Capacity (FVC) at Screening and Follow-up</title>
        <description>FEV1 and FVC are measures of lung function. FEV1 is defined as the maximal amount of air that can be forcefully exhaled in one second. FVC is defined as the maximum amount of air that can be forcibly blown out after a maximum inspiration. FEV1 and FVC measurements were repeated until three technically acceptable measurements (within 150 milliliters of each other) had been made. Only the best of three measurements were recorded.</description>
        <time_frame>Screening (up to 30 days prior to Day 1) and Follow-up (approximately Day 19)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Participants received four inhalations of matching placebo (from four inhalation devices) once daily for 14 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Part B: GSK2269577 100 µg</title>
            <description>Participants received repeat doses of GSK2269557 100 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O3">
            <title>Part B: GSK2269577 200 µg</title>
            <description>Participants received repeat doses of GSK2269557 200 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
          </group>
          <group group_id="O4">
            <title>Part B: GSK2269577 500 µg</title>
            <description>Participants received repeat doses of GSK2269557 500 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O5">
            <title>Part B: GSK2269577 700 µg</title>
            <description>Participants received repeat doses of GSK2269557 700 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 100 µg, 500 µg, or placebo.</description>
          </group>
          <group group_id="O6">
            <title>Part B: GSK2269577 1000 µg</title>
            <description>Participants received repeat doses of GSK2269557 1000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
          </group>
          <group group_id="O7">
            <title>Part B: GSK2269577 2000 µg</title>
            <description>Participants received repeat doses of GSK2269557 2000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 500 µg.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Forced Expiratory Volume in One Second (FEV1) and Forced Vital Capacity (FVC) at Screening and Follow-up</title>
          <description>FEV1 and FVC are measures of lung function. FEV1 is defined as the maximal amount of air that can be forcefully exhaled in one second. FVC is defined as the maximum amount of air that can be forcibly blown out after a maximum inspiration. FEV1 and FVC measurements were repeated until three technically acceptable measurements (within 150 milliliters of each other) had been made. Only the best of three measurements were recorded.</description>
          <population>Safety Population</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FEV1, Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.586" lower_limit="1.093" upper_limit="2.079"/>
                    <measurement group_id="O2" value="1.387" lower_limit="0.783" upper_limit="1.99"/>
                    <measurement group_id="O3" value="1.533" lower_limit="0.784" upper_limit="2.282"/>
                    <measurement group_id="O4" value="1.558" lower_limit="0.916" upper_limit="2.199"/>
                    <measurement group_id="O5" value="1.573" lower_limit="1.092" upper_limit="2.055"/>
                    <measurement group_id="O6" value="1.36" lower_limit="1.126" upper_limit="1.594"/>
                    <measurement group_id="O7" value="1.407" lower_limit="0.768" upper_limit="2.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.494" lower_limit="1.174" upper_limit="1.813"/>
                    <measurement group_id="O2" value="1.272" lower_limit="0.69" upper_limit="1.855"/>
                    <measurement group_id="O3" value="1.523" lower_limit="0.775" upper_limit="2.271"/>
                    <measurement group_id="O4" value="1.34" lower_limit="1.092" upper_limit="1.589"/>
                    <measurement group_id="O5" value="1.501" lower_limit="0.989" upper_limit="2.013"/>
                    <measurement group_id="O6" value="1.405" lower_limit="0.948" upper_limit="1.861"/>
                    <measurement group_id="O7" value="1.431" lower_limit="0.834" upper_limit="2.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" lower_limit="2.476" upper_limit="3.624"/>
                    <measurement group_id="O2" value="3.08" lower_limit="1.901" upper_limit="4.259"/>
                    <measurement group_id="O3" value="3.632" lower_limit="2.585" upper_limit="4.679"/>
                    <measurement group_id="O4" value="4.348" lower_limit="3.565" upper_limit="5.131"/>
                    <measurement group_id="O5" value="3.277" lower_limit="2.389" upper_limit="4.164"/>
                    <measurement group_id="O6" value="2.958" lower_limit="1.6" upper_limit="4.316"/>
                    <measurement group_id="O7" value="3.156" lower_limit="2.099" upper_limit="4.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.96" lower_limit="2.432" upper_limit="3.488"/>
                    <measurement group_id="O2" value="3.042" lower_limit="1.809" upper_limit="4.275"/>
                    <measurement group_id="O3" value="3.764" lower_limit="2.533" upper_limit="4.995"/>
                    <measurement group_id="O4" value="4.192" lower_limit="3.527" upper_limit="4.857"/>
                    <measurement group_id="O5" value="3.137" lower_limit="2.057" upper_limit="4.217"/>
                    <measurement group_id="O6" value="3.03" lower_limit="1.691" upper_limit="4.369"/>
                    <measurement group_id="O7" value="3.192" lower_limit="1.968" upper_limit="4.416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs), defined as those events occurring from the start of treatment until follow-up (up to approximately 19 days), are reported.</time_frame>
      <desc>SAEs and non-serious AEs are reported for members of the Safety Population, comprised of all participants who received at least one dose of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part A: Placebo</title>
          <description>Participants received 2 inhalations of matching placebo once daily for 14 consecutive days.</description>
        </group>
        <group group_id="E2">
          <title>Part A: GSK2269577 1000 µg</title>
          <description>Participants received repeat doses of GSK2269557 1000 micrograms (µg) (2 inhalations of 500 µg each from a single device) administered as a dry powder inhalation, once daily for 14 consecutive days.</description>
        </group>
        <group group_id="E3">
          <title>Part B: Placebo</title>
          <description>Participants received four inhalations of matching placebo (from four inhalation devices) once daily for 14 consecutive days.</description>
        </group>
        <group group_id="E4">
          <title>Part B: GSK2269577 100 µg</title>
          <description>Participants received repeat doses of GSK2269557 100 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
        </group>
        <group group_id="E5">
          <title>Part B: GSK2269577 200 µg</title>
          <description>Participants received repeat doses of GSK2269557 200 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 100 µg or placebo.</description>
        </group>
        <group group_id="E6">
          <title>Part B: GSK2269577 500 µg</title>
          <description>Participants received repeat doses of GSK2269557 500 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
        </group>
        <group group_id="E7">
          <title>Part B: GSK2269577 700 µg</title>
          <description>Participants received repeat doses of GSK2269557 700 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 100 µg, 500 µg, or placebo.</description>
        </group>
        <group group_id="E8">
          <title>Part B: GSK2269577 1000 µg</title>
          <description>Participants received repeat doses of GSK2269557 1000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing either GSK2269557 500 µg or placebo.</description>
        </group>
        <group group_id="E9">
          <title>Part B: GSK2269577 2000 µg</title>
          <description>Participants received repeat doses of GSK2269557 2000 µg administered as a dry powder inhalation, once daily for 14 consecutive days. To maintain blinding, the total dose was delivered through four inhalation devices, each device containing GSK2269557 500 µg.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vessel puncture site inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

